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ABSTRACT 
 
 
One of the most devastating complications affecting infants and children with 
intestinal failure is parenteral nutrition-associated liver disease (PNALD). PNALD is a 
progressive disease that can lead to liver failure and death. In many cases, children 
require liver and small bowel transplantation, prolonged hospitalization and home care. 
Intravenous infusion of a fish oil emulsion has been shown to be efficacious for the 
treatment of PNALD. The therapeutic mechanism is unknown, but is thought to occur via 
anti-inflammatory pathways, as of yet undefined. Fish oil contains omega-3 
polyunsaturated long-chain fatty acids (ω3PUFA) that have anti-apoptotic and anti-
inflammatory effects. This body of work is focused on my central hypothesis that 
PNALD is attenuated by ω3PUFA via anti-apoptotic and anti-inflammatory mechanisms. 
I have used both cultured hepatocytes and macrophages and a preterm neonatal pig model 
to show that ω3PUFA attenuate both apoptosis and inflammation associated with 
PNALD. Although there are still many unanswered questions concerning the mechanism 
of ω3PUFA in the treatment of PNALD, this work supports the efficacy of this novel 
therapy for treating PNALD. 
 v 
PREFACE 
 
 
In December 2007 during my clinical pharmacy practice residency, I became very 
interested in parenteral nutrition-associated liver disease (PNALD). In the first six 
months of my residency training, I observed the deaths of two infants from PNALD. I 
had read case studies reporting the use of a fish oil-based intravenous fat emulsion for the 
treatment of PNALD. This product is not FDA-approved; therefore, we were unable to 
obtain it for use at our institution. I approached my faculty preceptors about using enteral 
fish oil for the treatment of PNALD, and the treatment was initiated in six patients with 
PNALD. Complete reversal of disease occurred in four patients, and improvement was 
observed in the remaining two patients. This experience was the basis for the work 
presented in chapter 2.  
 
In July 2008, I completed my residency and began a fellowship training program 
specializing in pediatric nutrition and metabolic support. I realized that, at best, a clinical 
study would yield safety and efficacy data within the next few years. However, we would 
probably still know very little about the mechanism by which fish oil attenuates PNALD. 
My curiosity led me to develop a research program to determine the mechanism.  
 vi 
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CHAPTER 1.    PARENTERAL NUTRITION-ASSOCIATED LIVER DISEASE* 
 
 
Introduction 
 
 
Definition and etiology 
 
Parenteral nutrition (PN)-associated liver disease (PNALD) is defined as a 
decrease in bile flow, independent of mechanical obstruction, in patients receiving 
prolonged PN and with no other underlying cause of liver disease (1-6). PNALD is also 
referred to as PN-associated cholestasis (PNAC), PN-associated liver injury (PNALI), or 
more recently intestinal failure-associated liver disease (IFALD). Because PNALD 
typically improves with the advancement of enteral nutrition (EN) and the 
discontinuation of PN (7), and IFALD encompasses patients that necessitate specialized 
nutrition support such as EN and/or PN, I have chosen to use PNALD throughout the 
manuscript. 
 
Clinical diagnosis of PNALD includes biochemical markers for liver disease such 
as aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin 
(TB), and direct bilirubin (DB), and ruling out all other potential causes of liver disease. 
Although liver biopsy is needed to definitively diagnose PNALD, because of the invasive 
nature of biopsy, many centers will not perform diagnostic liver biopsies and consider 
DB > 2 or 3 mg/dL in the absence of any other liver etiology reflective of PNALD. 
PNALD is reported to occur in 50–66% of children receiving long-term PN, with a 
higher incidence in premature neonates (1-3, 8, 9). Although the incidence of PNALD is 
much higher in children, PNALD also occurs in adult patients, but may present as 
cholestasis, hepatosteatosis, or cholelithiasis.  
 
PNALD is one of the most devastating complications affecting infants receiving 
PN. The etiology of PNALD is not well understood and is likely multi-factorial (1-3, 8, 
10). Risk factors include immature liver function, inflammation, oxidative stress, 
infection (specifically sepsis), nutrient deficiencies, and contaminants in parenteral 
products, and macronutrient provisions including intravenous fat emulsion (IVFE) and 
proteins (11-14). PNALD can progress from cholestasis to cirrhosis, liver failure, and 
death if not treated by advancement to full EN with discontinuation of PN. In cases where 
full enteral feeding is not possible, the patient may require liver and small bowel 
transplantation, which is also associated with significant morbidity and mortality.  
 
 
 
 
 
 
*Adapted with permission. Tillman EM. Review and clinical update on parenteral 
nutrition-associated liver disease. Nutr Clin Pract 2012.28(1):30-9. 
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Pathophysiology of PNALD 
 
The lack of EN can lead to a decrease in the release of counter-regulatory 
hormones secreted from the gut, which can decrease bile flow. In premature infants, 
organ systems are not developed to the extent they are in a term infant and/or adult, 
which can result in a build-up of toxic intermediates from parenteral products, which in 
turn can have harmful effects on the hepatobiliary system (15). Methionine, as an 
example, is known to be hepatotoxic in immature rabbit pups, and the very high 
concentrations of methionine in the plasma of neonates and infants receiving standard 
adult amino acid formulations may result in liver injury in the neonate (16). Aluminum 
contamination is unavoidable in parenteral products. Neonates receiving PN have been 
estimated to receive aluminum ranging from 10-60 µg/kg/day (17). Exposure to 
aluminum has been shown to decrease bile flow by decreasing bile acid transport proteins 
(17). This may be even more profound in neonates with immature bile acid transport 
systems (15). Alemmari et al. developed a pig model to study aluminum effects on 
hepatic function. They showed that bile acid concentrations and hepatic aluminum 
concentration correlated with duration of aluminum exposure (18). The same authors 
evaluated incidence and severity of PNALD in this neonatal pig model given standard PN 
solution vs. a low aluminum PN solution. The investigators observed more severe 
histological changes in the standard PN group compared to the low aluminum group, but 
they did not find a significant difference in serum direct bilirubin or bile acids (17).   
 
Intravenous fat emulsions have been of particular interest in PNALD, as ω6 
polyunsaturated fatty acid (PUFA) soybean-based lipid emulsions are thought to be pro-
inflammatory, as well as contain potentially toxic phytosterols (19). Composition and 
dose of soybean-based IVFE have been associated as risk factors for cholestasis, as well 
as recent packaging changes of IVFE associated with fat globules > 5 μm (13, 20). In 
animal studies, unstable IVFE administration resulted in increased oxidative stress and 
liver injury (21).  
 
The development of PNALD is associated with increased morbidity and 
mortality, and, if not reversed, PNALD can progress to liver fibrosis, hepatic failure and 
death. PNALD improves with the initiation of enteral feeding. While most PNALD 
reverses with advancement of EN and discontinuation of PN, this is not an option in 
many patients with anatomic or functional short bowel syndrome (SBS). 
 
 
Treatments for PNALD 
 
Many treatments for PNALD have been reported to have limited success. They 
include PN cycling, drug therapy with ursodeoxycholic acid, cholecystokinin, oral 
antibiotics and nutrient restriction, including limiting soybean-based IVFE and providing 
conservative protein and dextrose calories to prevent overfeeding (22-26). Advancement 
to full EN and discontinuation of PN is the best treatment for PNALD. In a retrospective 
study by Javid et al. 12 patients were evaluated and determined to have PNALD; only 
two of these patients had improvement in serum bilirubin prior to the achievement of full 
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EN, whereas the mean time of normalization of bilirubin in the remainder of the patients 
was four months after discontinuation of PN (7). Although achievement of full EN is 
associated with resolution of PNALD, this is not possible for many patients with SBS. 
Surgical approaches, such as the serial transverse enteroplasty (STEP) bowel lengthening 
procedure, have been used to decrease need for PN (5). Intestine/intestine + liver 
transplantation have also been lifesaving for patients with progressive PNALD (4, 27). 
However, these are invasive surgical procedures that have a high risk of complications, 
including bleeding, infection and rejection (in transplant) (4, 27). Most of the recent 
progress in treating PNALD has been related to IVFE. This includes the use of parenteral 
fish oil-based IVFE, Omegaven®, (Fresenius Kabi AG, Bad Homburg v.d.h., Germany) 
(28, 29), dose reduction of soybean-based IVFE, enteral administration of fish oil, and 
the use of contemporary IVFE products that provide a blend of ω3-, ω6-, and ω9PUFA 
(30). 
 
Cyclic parenteral nutrition. Cyclic PN has been anecdotally thought to decrease 
the incidence and severity of PNALD, but there is very limited evidence to support this 
observation. Jensen et al. performed a retrospective review to evaluate if prophylactic 
cycling decreased the incidence and the time of onset of PNALD in patients with 
gastroschisis. Thirty-six infants were prophylactically cycled and were compared to 71 
control patients that received continuous PN. The authors reported that infants receiving 
continuous PN were 2.86 times more likely to develop PNALD as compared to controls, 
but after adjusting for confounding factors, this failed to meet statistical significance (26). 
Salvador et al. conducted a prospective randomized study to evaluate the effect of cycling 
PN in very low birth weight infants on the incidence of PNALD. In this study, the control 
group (n = 36) received continuous PN (amino acid and dextrose solution over 24 hours 
and lipids over 18 hours in accordance with hospital protocol), and the treatment group (n 
= 34) received cyclic PN (amino acid solution over 20 hours, lipids over 18 hours, and 
dextrose over 24 hours). Infants requiring abdominal surgery were excluded from this 
study because they required transfer to a surgical referral center. The incidence of 
PNALD was similar in both groups (32% in the treatment group and 31% in the control 
group). The authors concluded that early prophylactic cyclic PN is not a significant 
predictor for the development of PNALD (31). In this study, the only macronutrient that 
was provided over different lengths of time in this study was protein. All patients 
received continuous dextrose and all patients received cycled IVFE. Additionally, 
patients requiring abdominal surgery typically have a longer duration of PN dependence 
and are at higher risk for the development of PNALD. Exclusion of these patients may be 
a flaw of the study. 
 
Parenteral ω3 polyunsaturated fatty acids. The first reports of using fish oil-
based IVFE in children came from the Boston Children’s Hospital. They reported the 
case of a 17-year-old male who developed essential fatty acid deficiency (EFAD) due to a 
soy allergy preventing administration of soybean-based IVFE. The patient was treated 
with parenteral fish oil comprised primarily of ω3PUFA and limited ω6PUFA; EFAD 
was reversed. Clinicians also observed decreases in AST, ALT, TB, and DB (28). In 
2006, the Boston group reported the complete reversal of PNALD in two infants with 
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intestinal failure treated with fish oil-based IVFE at 1 g/kg/day. Cholestasis resolved in 
both infants within the first 60 days of treatment (29).  
 
The same group published safety and efficacy data for 18 patients treated with 
fish oil-based IVFE at 1 g/kg/day infused over 12 h per day from September 2004 – 
August 2006 compared to 21 historical control patients who received standard soy-based 
lipid emulsions 1 – 4 g/kg/day infused over 24 h per day between 1986 - 1996. They 
reported the time to reversal of cholestasis of 9.4 weeks in the fish oil-based IVFE group 
compared to 44 weeks in the control group (p = 0.002; (32). There were two deaths and 
no liver transplants reported in the fish oil-based IVFE group compared to seven deaths 
and two liver transplants in the control group. Death occurred at 6.7 and 10.7 weeks 
respectively in the two patients in the fish oil group, whereas the time to death in the 
historic control group was reported as a median of 41 weeks. Although the initial findings 
are interesting, this study is limited by the small sample size and a control group that is 
from an observation period 10 – 20 years prior to the treatment group. Standards of care 
and infant survival have changed in the last 20 years. Also, the dose of IVFE was 
significantly decreased in the treatment group. These results could be interpreted as 
suggesting that reduction of IVFE resulted in the improved outcomes.  Puder et al. 
published results of an open-label study of 42 infants treated with fish oil-based IVFE 
between August 2006 and November 2007 compared to a historical cohort of 49 patients 
with SBS and PNALD treated with soybean-based IVFE from 1999 – 2006 (33). This 
report is an extension of the previously published work from this group with a slightly 
more contemporary historical cohort. Death occurred in three of 42 (7%) patients in the 
fish oil group and 12 of 49 (24%) in the control group. One patient receiving fish oil 
underwent liver transplant compared to six patients in the control group.(33) The median 
time to discontinuation of PN was four weeks in the fish oil group as compared to 20 
weeks in the control group. PNALD resolved while patients were still receiving PN in 19 
patients in the fish oil group and only two patients in the control group (33). Patients in 
the fish oil group had lower international normalized ratio (INR) values and increased 
platelet counts compared to the control group, suggesting that fish oil has a limited effect 
on coagulation, but this conclusion is confounded by the higher incidence of advanced 
liver disease in the control group.   
 
Similar success has also been observed by Italian clinicians in a case of an infant 
with severe PNALD (34). The patient was started at 0.2 g/kg/day of fish oil-based IVFE 
and advanced by 0.2 g/kg/day to achieve a dose of 1.5 g/kg/day, which is higher than has 
been previously reported (34). Chinese clinicians reported the reversal of PNALD in 
three of four infants with intestinal failure treated with fish oil-based IVFE (35). In these 
patients, standard soybean oil-based IVFE was discontinued and fish oil-based IVFE was 
initiated at 1 g/kg/day (35). Calhoun and Sullivan report successful resolution of PNALD 
in a 17-month-old infant with SBS after treatment with fish oil-based IVFE (36). Chung 
et al. reported the use of fish oil-based IVFE to treat four patients with SBS and PNALD 
(37). 
 
A study from Toronto recently reported the reversal of PNALD in nine of 12 
infants with SBS that were treated with a combination of a soybean oil-based IVFE and 
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fish oil-based IVFE. Four patients had complete reversal of PNALD while receiving a 
combination of soybean-based IVFE and fish oil-based IVFE, whereas the other five 
patients did not have reversal of disease until after soybean-based IVFE was discontinued 
(38). 
 
Early reports of fish oil-based IVFE used outcomes based on clinical presentation 
and biochemical markers of cholestasis (AST, ALT, TB and DB) and not based on liver 
biopsy results. Investigators from Boston have now reported 83 biopsy results taken in 66 
children. Of the 83 biopsies, 74 demonstrated fibrosis; eight of these also demonstrated 
cirrhosis. Forty-one of the 74 fibrotic biopsies (55%) were obtained in patients without 
biochemical evidence of cholestasis (39). Seventy percent of these patients were treated 
with fish-oil-based IVFE during his/her clinical course (39). Soden et al. reports similar 
findings with two infants who had improvement in biochemical markers of cholestasis, 
but persistent portal fibrosis despite treatment with fish oil-based IVFE (40). This report 
has been questioned because of the timing of the biopsy and the treatment with fish oil-
based IVFE. In contrast, an abstract from Dimmitt et al. reported multiple biopsy 
evaluation that showed fibrosis had resolved or was stable after switching to a fish oil-
based IVFE (41). Hepatocellular injury associated with PNALD has been reported to 
occur within the first few weeks of PN, and the reversal of fibrosis associated with any 
type of liver injury may never occur, but, if it does, reversal often takes a long time (42, 
43). 
 
While much of the use of fish oil-based IVFE has been in pediatric patients, 
Burns and Gill reported similar success in treating a 50-year-old female patient with 
PNALD with fish oil-based IVFE (44). Although, the past five years has resulted in many 
publications evaluating fish-oil based IVFE, a recent systematic review of five 
randomized controlled trials and three high-quality prospective cohort studies concluded 
that there is still a lack of high-quality data to support the use of fish-oil based IVFE in 
children and future trials are needed to evaluate the safety and long-term outcomes (45). 
 
Modification of soybean-based IVFE and enteral fish oil. While fish oil-based 
IVFE appears to be a promising therapy for PNALD, its use in the United States is 
hindered by lack of FDA approval, thereby necessitating the use of an investigational 
new drug (IND) application. Because of the difficulty in obtaining the parenteral fish oil 
product, some institutions have restricted or eliminated soybean-based IVFE and used 
enteral fish oil (250 mg/kg/d; J.R. Carlson Laboratories, Arlington Heights, IL) to treat 
infants with PNALD. Rollins et al. retrospectively evaluated 26 patients with SBS 
receiving soybean-based IVFE 2 – 3 g/kg/day: 23 patients developed PNALD. PNALD 
resolved in 10 patients with the advancement of EN, one patient developed PNALD and 
remained on 2 g/kg/day of soybean-based IVFE, three patients required liver transplant, 
three patients died, and six patients had complete resolution of PNALD with the removal 
of soybean-based IVFE. Four of these six patients also received enteral fish oil (46).  
 
Our group has reported six infants with PNALD treated with enteral fish oil (dose 
ranging from 0.15-1 g/kg/d using three different commercially available products) (47). 
PNALD completely reversed in four of the six infants supplemented with enteral fish oil 
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within a mean of five weeks after initiation of therapy. The two infants that did not have 
complete resolution of disease had some improvement in bilirubin and liver enzymes 
while on enteral fish oil. One of these non-responding infants had an extremely short gut, 
estimated as 8 cm of small bowel remaining, and no ileocecal valve. This would suggest 
that absorption is limited in the extremely short gut patient, but does not rule out an 
intraluminal effect of fish oil. Similar results were observed by Sharma et al. when four 
infants had resolution of PNALD after being treated with enteral fish oil (48).  
 
Cober et al. conducted a prospective study evaluating dose reduction of soybean-
based IVFE to improve PNALD in infants. Soybean-based IVFE were reduced to 1 
g/kg/day two days per week in the treatment group and these patients were matched with 
historical controls that received daily soybean-based IVFE at a dose of 3 g/kg/day. 
Patients receiving the restricted IVFE dosing had a significant decrease in direct bilirubin 
as compared to historical controls. Eight of the 31 infants in the restricted IVFE group 
were reported as having mild essential fatty acid deficiency, but this was reversed when 
an additional day of IVFE was added (49). Nehra et al., retrospectively evaluated 61 
patients that received either 1 g/kg/day soybean-based IVFE or 2-3 g/kg/day soybean 
based IVFE. They found that restricting soybean-based IVFE to 1 g/kg/day did not 
prevent PNALD in neonates (50). 
 
Other contemporary lipids. European clinicians and researchers have utilized 
other IVFE products in addition to fish oil-based IVFE. An IVFE comprised of soybean 
oil, medium-chain triglycerides, olive oil and fish oil (SMOFlipid 20%, Fresenius Kabi 
AG, Bad Homburg v.d.h., Germany) has also been used for the treatment of PNALD. In a 
randomized, double-blind trial of 22 patients treated with SMOFlipid and 22 patients 
treated with olive oil and soybean oil IVFE for five days postoperatively there was no 
significant difference in baseline AST and ALT between the two groups; however, 
significantly lower AST and ALT values were observed at day two and day five in the 
SMOFlipid group as compared to the olive oil and soybean oil group (51). Muhammed et 
al. retrospectively compared serum bilirubin of 17 neonates with PNALD. Eight were 
treated with SMOFlipid and nine were continued on standard soybean-based IVFE. After 
six months of treatment, 63% of patients in the SMOFlipid group had resolution of 
PNALD compared to 22% in the soybean-based IVFE group (52). 
 
 
Adverse side effects associated with novel IVFE 
  
As with any new therapy, there may be potential adverse side effects. In the initial 
Boston cohort study, only one of 18 patients and two of 42 patients in the second cohort 
exhibited biochemical evidence of essential fatty acid deficiency (EFAD) based on 
triene:tetraene ratios (T/T); however, total fatty acid profiles were not reported in either 
study (32, 33). With decreased lipid dosing, it is possible to have T/T within the reference 
range, but have concentrations of individual fatty acids below the age-related reference 
range. A prospective evaluation of 10 patients receiving fish oil-based IVFE as a sole fat 
source at a dose of 1 g/kg/day resulted in T/T within the reference range in all 10 patients, 
but 50% of patients had linoleic acid concentrations below the reference range and 90% 
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had at least a 17% reduction in linoleic acid concentration after six weeks of treatment 
with fish oil-based IVFE (53). In the lipid restriction study by Cober et al., 25% of 
patients developed mild EFAD, which necessitated increasing the weekly dose of IVFE 
(49). All cases of EFAD corrected with the increase in lipid dose. Animal studies have 
not clarified the adequacy of linoleic acid intake with fish oil. A study of pair-fed mice 
provided with chow containing either soybean-based or fish oil-based fat showed fish oil 
both prevents EFAD and enhances growth in mice. EFAD was determined based on T/T. 
All T/T were within the reference range, but linoleic acid concentrations were not 
reported (54). 
 
One infant with SBS and PNALD treated with fish oil-based IVFE developed burr 
cell anemia that resolved upon discontinuation of fish oil-based IVFE (55). The authors 
speculated that incorporation of ω3PUFA within red blood cell membranes made 
erythrocytes susceptible to trapping and destruction within the spleen. The product 
labeling for the fish oil-based IVFE suggests that the product could increase bleeding risk 
(56). In contrast, Bays and Harris both conclude that ω3PUFA does not increase bleeding 
risk (57, 58).  
 
 
Animal Studies of ω3PUFA for the Treatment of Liver Disease  
 
Several animal models have been utilized to study the effects of ω3PUFA 
supplementation on liver injury. Alwayn et al. report the use of both enteral and 
parenteral ω3PUFA in a mouse model of NAFLD (59). Animals were randomized to 
receive standard chow or an enteral fat-free, high carbohydrate diet identical to parenteral 
nutrition solutions given to pediatric patients, with and without ω3PUFA 
supplementation. Mice fed standard chow had the lowest hepatic fat content and served 
as controls. Hepatic fat content was the highest in mice fed the liquid high carbohydrate 
diet, and was significantly decreased by both enteral and parenteral ω3PUFA 
supplementation (59). 
 
In a surgical model of liver injury, mice underwent a common bile duct ligation 
and were then randomized to receive a control soy diet rich in ω6PUFA or a Menhaden 
diet rich in ω3PUFA (60). In this study, there were trends that a Menhaden diet was 
hepato-protective against injury, but this was not statistically significant (60). 
 
A study in rabbits receiving a balanced PN regimen with 3 g/kg/day IVFE 
evaluated the effects of a soybean oil emulsion alone, an olive oil emulsion alone, and a 
combination soybean (2.8 g/kg/day) and fish oil (0.2 g/kg/day) emulsion. Animals that 
received the fish oil were found to have more extensive hepatic fibrosis than those that 
received the soybean or olive oil regimens (61). The authors speculated that this finding 
might be due to the omega-3 to omega-6 ratio of 1:6 in the emulsion studied, whereas 
optimal omega-3 to omega-6 ratios in animal models have ranged from 1:2 to 1:4 (62, 
63).  
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Potential Mechanism of Action of ω3PUFA 
 
Omega-3 PUFA supplementation has been used for the treatment of many 
inflammatory diseases, including cardiovascular disease, arthritis, asthma, sepsis, 
autoimmune disease and malignancy (57). ω3PUFA are thought to exhibit anti-
inflammatory effects by causing a shift from ω6PUFA-derived pro-inflammatory 
eicosanoids to the anti-inflammatory variety derived from ω3PUFA (64). This pathway is 
regulated by the Δ-5-desaturase enzyme system, which preferentially metabolizes 
ω3PUFA. A number of studies have suggested that positive changes in membrane 
phospholipid content, as well as in clinical outcomes, can be achieved with relatively low 
intakes of fish oil (65-68). This suggests that ω3PUFA compete very effectively as 
substrates for the Δ-5-desaturase enzyme system despite the presence of large amounts of 
ω6PUFA (Figure 1-1). 
 
Tumor necrosis factor (TNF)-α is one of the major pro-inflammatory cytokines 
involved in liver disease (69). In a murine macrophage model, the reduction of TNF-α 
gene transcription, via inactivation of the nuclear factor kappa-B (NF-κB) signal 
transduction cascade secondary to decreased IκB phosphorylation at serine 32, has been 
proposed as a mechanism for the anti-inflammatory effects of ω3PUFA (70). TNF-α and 
other pro-inflammatory cytokines transcribed via NF-κB, as well as stimulation of death 
receptors on the hepato-cellular surface, have been linked to liver injury, causing both 
apoptosis and necrosis in many types of liver diseases (cholestasis, NAFLD, alcoholic 
cirrhosis and hepatitis) (71). While the exact mechanism of action of ω3PUFA in 
PNALD is unclear, this anti-inflammatory pathway would seem to make sense based on 
potential etiologies of the disease. Li et al. reported that anti-tumor necrosis factor-α 
ameliorated the progression of PNALD and improved the expression of hepatic ABC 
transporter genes in a mouse model of PNALD (72). 
 
In addition to the anti-inflammatory effects of ω3PUFA, many investigators are 
studying the effects of phytosterols found in soybean-based IVFE on liver injury. 
Phytosterols act as antagonists to the nuclear receptors that are critically involved in 
hepato-protection from cholestasis (73), therefore the elimination or dose limitation of 
soybean-based IVFE may play a key role in the mechanism of liver injury observed in 
PNALD. Kurvinen et al. measured serum cholesterol, non-cholesterol sterols and liver 
biochemistries in 28 neonates and 11 children. Neonates with PNALD had significantly 
higher ratios of plant sterols and cholesterol compared to neonates without PNALD. 
Additionally, duration of PN was associated with concentrations of cholestanol, 
stigmasterol, avenasterol, AST, and ALT (74). These data suggest that plant sterols found 
in soybean-based IVFE may be responsible for liver injury observed in PNALD. 
 
The past five years have resulted in many changes in how clinicians are treating 
PNALD. There has also been increased excitement for research in this very important 
area. While there are still many unanswered questions, the current data suggest IVFE 
play a key role in PNALD. Restricting soybean-based IVFE, or providing fish oil either 
parenterally or enterally may be a potential treatment for patients with PNALD. It is clear 
from the treatment failures reported from many centers across the world that fish oil is  
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Figure 1-1: Omega-3 and omega-6 long-chain polyunsaturated fatty acid 
metabolism. 
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not a universal cure for all patients. Recent biopsy reports from patients treated with fish 
oil-based IVFE that showed hepatic fibrosis with no biochemical evidence of cholestasis 
is of concern (39, 40). Contemporary IVFE solutions, such as the SMOFlipid product that 
offers a blend of ω3PUFA, ω6PUFA and ω9PUFA, may be an advantage in the treatment 
of PNALD. A well-balanced lipid product may have advantages over a single-source 
product. Several centers leading research efforts against intestinal failure and PNALD 
have established inter-professional teams to attack this multifactorial disease from all 
angles (19, 75, 76). This approach to the care of this disease will likely result in the most 
favorable patient outcomes. More research in the form of randomized controlled trials 
evaluating dosing of ω3PUFA, as well as other potential drug therapies, are needed to 
advance our knowledge and treatment of PNALD. 
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CHAPTER 2.    IMPROVEMENT OR REVERSAL OF PARENTERAL 
NUTRITION-ASSOCIATED LIVER DISEASE IN SIX INFANTS WITH 
SHORT BOWEL SYNDROME TREATED WITH ENTERAL FISH OIL* 
 
 
Introduction 
 
Parenteral nutrition (PN)-associated liver disease (PNALD) is defined as a 
decrease in bile flow that occurs independent of mechanical obstruction in patients 
receiving prolonged parenteral nutrition (1-3). It is diagnosed by clinical presentation, 
and elevation in direct bilirubin, liver enzymes, and serum bile acids (1-3). PNALD 
occurs in approximately 25 – 66% of patients maintained on long-term PN, and incidence 
increases in infants with low birth weight, low gestational age and short bowel syndrome 
(SBS) (1-3, 8). The etiology of PNALD is not well understood and likely multifactorial. 
If not reversed, PNALD can progress from cholestasis to liver fibrosis, hepatic failure 
and death (1). PNALD improves with the initiation of enteral nutrition (EN) and 
discontinuation of PN, but many patients with SBS are dependent on PN.  
 
Fish oil-based intravenous fat emulsion (IVFE), Omegaven® (Fresenius Kabi AG, 
Bad Homburg v.d.h., Germany) appears to be a promising therapy in the treatment of 
PNALD.(28, 29, 32-38) However, its lack of food and drug administration (FDA) 
approval requires use under an investigational new drug (IND) application. Due to the 
difficulty in obtaining the parenteral fish oil, restriction of soybean-based IVFE and 
enteral fish oil have been utilized. Rollins et al. reported complete resolution of PNALD 
with the removal of soybean-based IVFE in six patients, four of whom also received 
enteral fish oil (46). In contrast, we report the use of enteral fish oil to treat PNALD with 
no change in soybean-based IVFE. Fish oil products are shown in Table 2-1. 
 
 
Case Reports 
 
Six infants with PNALD (diagnosis based on elevated total bilirubin, PN 
dependence and ruling out other potential causes of liver disease) receiving a 
combination of PN and EN were supplemented with enteral fish oil and no change in 
parenteral lipids. All patients received the institutional standard of care treatment for 
PNALD including the initiation and advancement of EN as tolerated, cyclic PN to 
provide a PN-free period each day, and ursodiol. Enteral fish oil doses were targeted at 1 
g/kg/day based on previously published reports using fish-oil based IVFE, but dosing and 
product varied among patients due to the discretion of the clinician and doses were 
rounded to the nearest capsule, so dose ranged from 1 – 6 g/kg/day. Patients were 
required to have enteral access determined by his/her physician, but no minimum feeding  
 
*Adapted with permission. Tillman EM, Crill CM, Black DD, Hak EB, Lazar LF, 
Christensen ML, et al. Enteral fish oil for treatment of parenteral nutrition-associated 
liver disease in six infants with short-bowel syndrome. Pharmacotherapy 2011.31(5):503-
9. 
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Table 2-1: Fish oil product comparison.  
 
Product constituents Lovaza® Nature Made® Nature’s Bounty® Omegaven® 
Linoleic acid ---- ---- 10 10 - 70 
α-Linolenic acid ---- ---- 300 < 20 
EPA 465 160 180 125 - 282 
DHA 375 320 120 144 - 309 
Arachidonic acid ---- ---- ---- 10 – 40 
Glycerol ---- ---- ---- 250 
Egg phospholipid ---- ---- ---- 120 
Tocopherol 4 ---- 1 1.5 - 2.9 
 
---- Signifies that the information is not available from the manufacturer. Amounts given 
as mg/g of each product. DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid 
 
 
was necessary to qualify for initiation of enteral fish oil. Fish oil was administered by 
withdrawing the oil from the gelatin capsule and administering via mouth, nasogastric 
(NG), or gastrostomy (G) tube. Fish oil dosing and response to therapy are shown in 
Table 2-2. 
 
 
Patient 1 
 
A male born at 33 weeks gestation (birth weight 1053 grams) developed 
necrotizing enterocolitis (NEC) requiring a small bowel resection leaving approximately 
45 cm of small bowel and an intact ileocecal valve. At the time of arrival to our 
institution, the patient had developed PNALD. Postoperatively he was continued on PN 
and EN was slowly advanced. At nine months of age he was discharged home receiving 
65% PN cycled over 18 hours with 35% of calories provided enterally. 
 
By 11 months of age, he was receiving 40% of calories from EN and 60% from 
PN. Total bilirubin was 7.9 mg/dL, and he was prescribed 1 gram of fish oil four times 
per day (approximately 1 g/kg/day). Two weeks after starting enteral fish oil, the 
bilirubin had decreased to 1.4 mg/dL. At the clinic visit four weeks after starting fish oil, 
his previously notable jaundice had resolved and the total bilirubin had decreased to 0.7 
mg/dL. This dramatic improvement in bilirubin and clinical appearance occurred with 
only a modest 2 mL/hr increase in EN and no change to the PN regimen. Over the next 
four months, enteral feeding tolerance dramatically improved and by 17 months the 
patient was off PN and receiving full EN. At a clinic visit three months after initiation of 
enteral fish oil, it was discovered that his parents were giving him 1 gram of fish oil per 
day (0.15 g/kg) and not the 4 grams per day originally prescribed. At this time, PNALD 
had completely reversed and therefore, the dose was not increased.  
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Table 2-2: Nutrition, treatment and outcome data. 
 
Patient outcomes 1 2 3 4 5 6 
Total nutrition PN + EN 
(kcal/kg/day) 
100 120 115 105 115 130 
% EN at initiation of 
fish oil* 
37% 56% 94% 100% 25% 20% 
Dose of fish oil 
(g/kg/day) 
0.15 0.87 1 0.8 0.6 0.6 
Dose of fish oil (g/day) 1 3 6 3 3 2 
Fish oil product‡ 1 2 2 2 3 3 
Dose of IVFE 
(g/kg/day)§ 
0.9 0.6 1 1 0.8 0.8 
Omega-3 to omega-6 
ratio 
1:20 1:5 1:5 1:8 1:5 1:5 
Total bilirubin at 
initiation of fish oil 
(mg/dL) 
7.9 7.2 6.2 9.5 8.6 9.6 
AST/ALT at initiation of 
fish oil (units/L) 
218/119 132/95 206/169 398/232 233/113 173/110 
Weeks of fish oil prior 
to reversal 
2 4 6 N/A 6 N/A 
Total bilirubin 6 weeks 
after fish oil (mg/dL) 
0.5 1.5 0.7 5.3 2 77 
AST/ALT 6 weeks after 
initiation of fish oil 
(units/L)  
35/65 120/65 89/65 199/91 109/117 144/88 
 
*All patients were receiving continuous feedings with an infant hydrolysate formula. 
Although some patients were at or near goal EN initially, they had a long history of EN 
intolerance and poor weight gain that resulted in varying amounts of EN given during the 
time of enteral fish oil supplementation. ‡Fish oil products: 1) Nature Made; 2) Nature’s 
Bounty; 3) Lovaza. §A soybean oil-based IVFE was used in all patients. PN, parenteral 
nutrition; EN, enteral nutrition; IVFE, intravenous fat emulsions; AST, aspartate 
aminotransferase; ALT, alanine aminotransferase. 
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Patient 2 
 
A female born at 31 weeks gestation (birth weight 692 grams) developed a small 
bowel obstruction that required a small bowel resection and jejunostomy, leaving 
approximately 35 cm of small bowel with an intact ileocecal valve. Postoperatively she 
continued on PN and developed PNALD. She underwent reanastamosis at three months 
of age, and by nine months of age she was still receiving a combination of PN and EN 
was slowly being advanced. Bilirubin remained elevated and enteral fish oil was initiated 
at 0.9 g/kg/day, feeding tolerance improved, and PNALD reversed after four weeks. Six 
weeks after initiation of enteral fish oil, the patient was tolerating full EN and PN was 
discontinued. 
 
 
Patient 3  
 
A male born at 30 weeks gestation (birth weight 1425 grams) developed NEC that 
required a small bowel resection, jejunostomy and mucous fistula, leaving approximately 
20 cm of small bowel with an intact ileocecal valve. Postoperatively he was maintained 
on PN with supplemental EN and developed PNALD. He underwent reanastamosis 
approximately three months after his small bowel resection and, by six months of age, he 
was still receiving a combination of PN and EN was slowly being advanced. At six 
months of age enteral fish oil was initiated at 1 g/kg/day. Bilirubin decreased, enteral 
feeding tolerance improved and six weeks after initiation of enteral fish oil, PNALD had 
reversed. Of note, PNALD resolved despite interruptions in EN due to feeding 
intolerance. He was advanced to full EN and PN was discontinued ten weeks after 
initiation of enteral fish oil. 
 
 
Patient 4  
 
A male born at 28 weeks gestation (birth weight 1001 grams) developed NEC 
requiring ileal resection and jejunostomy placement, leaving approximately 60 cm of 
small bowel and an intact ileocecal valve. Postoperatively he was maintained on PN and 
developed PNALD. He underwent reanastamosis and gastrostomy tube placement at 
three months of age. He continued on PN while EN was slowly being advanced. At six 
months of age, the patient had progressive PNALD with a bilirubin of 9.5 mg/dL and 
international normalized ratio (INR) of 1.3. Enteral fish oil was initiated at 1 g/kg/day, 
and within four weeks the bilirubin decreased to 4.6 mg/dL. A gastrointestinal tract bleed 
developed and he was made NPO, requiring discontinuation of EN and enteral fish oil, 
and treated with parenteral vitamin K. Bilirubin, transaminases, and INR subsequently 
increased and platelet count decreased over the next several weeks. Blood cultures were 
positive for E. coli and Gram-positive cocci, and clinical status declined, requiring 
transfer to the intensive care unit where his bleeding was managed with vitamin K, 
platelets, and fresh frozen plasma. Overwhelming sepsis and hepatic failure ultimately 
led to the patient’s death. 
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Patient 5 
 
A female born at 27 weeks gestation (birth weight 626 grams) developed NEC at 
one week of age requiring a small bowel resection and jejunostomy placement, leaving 
approximately 32 cm of small bowel with an intact ileocecal valve and three ostomies. 
Postoperatively she was maintained on PN with slow advancement of EN and developed 
PNALD. She underwent reanastamosis approximately three months after her small bowel 
resection and by eight months of age, she was still receiving a combination of PN and EN 
was slowly being advanced. At eight months of age enteral fish oil was initiated at 0.6 
g/kg/day. Bilirubin decreased, enteral feeding tolerance improved and six weeks after 
initiation of enteral fish oil, PNALD had reversed. She was advanced to full EN and PN 
was discontinued nine weeks after initiation of enteral fish oil. 
 
 
Patient 6 
 
A female born at 26 weeks gestation (birth weight 600 grams) developed NEC 
with multiple perforations requiring extensive resections including the loss of the 
ileocecal valve. A jejunostomy was performed, leaving approximately eight centimeters 
of small bowel that was reanastamosed three months later. Postoperatively she was 
maintained on PN and trophic EN and developed PNALD. At six months of age, she was 
receiving PN with minimal EN (2 mL/hr continuous feedings) and bilirubin remained 
increased at 9.6 mg/dL. Enteral fish oil was started (0.6 g/kg/day) and bilirubin decreased 
to 7 mg/dL; however, she continued to experience feeding intolerance. After six weeks of 
enteral fish oil, and bilirubin was 7 mg/dL. She developed bloody stools, and EN and fish 
oil were stopped for two weeks. Her INR had not changed from values prior to starting 
enteral fish oil. During the two weeks that she was NPO, her bilirubin increased to 9.4 
mg/dL. When EN and fish oil were restarted bilirubin decreased. Six months after 
initiation of enteral fish oil, the patient was still on PN with supplemental EN and 
bilirubin was approximately 7 mg/dL. She was discharged on a combination of PN, EN, 
and enteral fish oil. This patient had multiple readmissions to the hospital for central 
venous line infections and there have been several occasions where enteral fish oil was 
temporarily discontinued. Each time enteral fish oil was stopped, bilirubin increased, and 
then it decreased upon re-initiation of enteral fish oil. The patient is now three years old 
and is currently on the small bowel and liver transplant list. 
 
 
Discussion 
 
Notable improvement in PNALD and EN advancement was associated with 
initiation of enteral fish oil in four of the six patients. EN is thought to be the most 
important factor in the prevention and treatment of PNALD. Horslen et al. reported 
improved enteral tolerance in infants with short bowel syndrome and end stage liver 
disease after liver transplantation (77). This suggests that the resolution of liver disease, 
whether it occurs via transplantation or medical management, may have a positive impact 
on enteral tolerance. In contrast, Javid et al. retrospectively evaluated 12 infants with 
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PNALD and observed reversal of PNALD in only two patients on PN while enteral feeds 
were advancing. PNALD did not reverse in the other 10 patients until approximately four 
months after PN was discontinued and patients were receiving full EN (78). In our 
patients, it is not clear if the addition of enteral fish oil is entirely responsible for the 
dramatic improvement in PNALD and EN tolerance, or if the reversal of PNALD may 
have been attributed to increased EN. 
 
Improvement of liver function was first described in case reports after 
administration of fish oil-based IVFE (28, 29). These initial reports were followed by 
safety and efficacy data for 18 patients treated with fish oil based-IVFE compared to 21 
historical control patients who received standard soybean oil-based IVFE. The time to 
reversal of cholestasis was 9.4 weeks in the fish oil group compared to 44 weeks in the 
control group (32). Although these initial findings are interesting, this study is limited by 
the small sample size and a control group that is from an observation period 10 – 20 years 
prior to the treatment group. Also, the dose of lipids was significantly decreased in the 
treatment group. In addition, these investigators published results of an open-label study 
of 42 infants treated with fish oil-based IVFE compared to a more contemporary 
historical cohort of 49 patients (33). The median time to discontinuation of PN was four 
weeks in the fish oil group compared to 20 weeks in the control group. PNALD resolved 
while patients were still receiving PN in 19 patients in the fish oil group but only two 
patients in the control group (33).  
 
A study from Toronto recently reported the reversal of PNALD in nine of 12 
infants with SBS treated with a combination of a soybean oil-based IVFE and fish oil-
based IVFE (1 g/kg/day soybean oil-base IVFE and 1 g/kg/day fish oil-based IVFE). 
Four patients had reversal of PNALD while receiving a combination of soybean-based 
IVFE and fish oil-based IVFE, whereas the other five patients did not have reversal of 
disease until after soybean-based IVFE was discontinued (38). 
 
Italian clinicians reported success with fish oil-based IVFE in a case report of an 
infant with severe PNALD (34). The patient was started at 0.2 g/kg/day of fish oil-based 
IVFE and advanced by 0.2 g/kg/day to achieve a dose of 1.5 g/kg/day, which is higher 
than has been previously reported (34). Chinese clinicians report the reversal of PNALD 
in three of four infants with intestinal failure treated with fish oil-based IVFE (35). In 
these patients, standard soybean oil-base IVFE was discontinued and fish oil-based IVFE 
was initiated at 1 g/kg/day (35). Calhoun and Sullivan report resolution of PNALD in a 
17-month-old infant with SBS after treatment with fish oil-based IVFE (36). Chung et al. 
reported successful treatment of PNALD with fish oil-based IVFE in four patients (37). 
 
Rollins et al. retrospectively evaluated 26 patients with SBS and PNALD 
receiving soybean-based IVFE 2 – 3 g/kg/day. Ten patients had complete resolution of 
PNALD with advancement of EN, one patient with PNALD remained on 2 g/kg/day of 
soybean-based IVFE, three patients required liver transplant, three patients died, and six 
patients had complete resolution of PNALD with the removal of soybean-based IVFE. 
Four of these six patient also received enteral fish oil (46). This suggests that removal of 
soybean-based IVFE alone may be beneficial in the treatment of PNALD.  
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The optimal dosing of enteral fish oil has not been elucidated. Reports of fish oil-
based IVFE have utilized doses ranging from 1 – 1.5 g/kg/day as the exclusive source of 
fats (29, 32-38). In this case series, the dramatic improvement of PNALD observed in 
patient 1 with a dose of 0.15 g/kg/day suggests that doses much lower than what has been 
previously thought may provide benefit. 
 
We report bleeding in the two patients that did not have reversal of PNALD. 
Although bleeding is a possible adverse effect of fish oil, because omega-3 long-chain 
fatty acids competitively inhibit cyclooxygenase, thereby decreasing synthesis of 
thromboxane A2 from arachidonic acid leading to platelet aggregation, bleeding has not 
been significant in previous reports (28, 29, 32-38). Additionally, bleeding is often seen 
with the progression of liver disease; it is unclear if the bleeding these patients 
experienced was due to the enteral fish oil supplementation or the progression of liver 
disease. When the bleeding events occurred in our patients, the INR values were not 
greater than reported prior to starting enteral fish oil, suggesting that bleeding was not 
related to the enteral fish oil. Furthermore, evaluations of safety of fish oil in the adult 
cardiology population by Bays and Harris have both concluded that fish oil does not 
increase bleeding risk (57, 58).  
 
These cases have several variables that could have influenced time to reversal of 
PNALD independently of the administration of enteral fish oil. The literature reports a 
27% fatality rate and 11% transplant rate in historical controls receiving soybean-based 
IVFE (32, 33). In our six patients, only one patient died and no patients have yet required 
transplant. This case series report was retrospective, therefore laboratory evaluations 
were not conducted under a specific protocol and serial direct bilirubin concentrations 
were not available for all patients. Patients were outside of the period of neonatal 
jaundice; therefore, the total bilirubin should be highly reflective of the direct bilirubin. 
  
Because these patients all had SBS and questionable enteral absorption, fatty acid 
profiles are needed to confirm absorption. These observations are not part of routine care 
and therefore were not done. It is also possible that systemic absorption is not necessary 
to see some beneficial effect, but that the local effects of fish oil on the gastrointestinal 
mucosa and liver may play a role in the attenuation of inflammation, thereby attenuating 
hepatocellular damage associated with PNALD. Alwayn et al. report the use of both 
enteral and parenteral fish oil administration in a mouse model of nonalcoholic fatty liver 
disease (59). Animals were randomized to receive standard chow or an enteral fat-free, 
high carbohydrate diet identical to PN, with and without fish oil. Mice fed standard chow 
had the lowest hepatic fat content and served as controls. Hepatic fat content was the 
highest in mice fed the liquid high carbohydrate diet, and was significantly decreased by 
both enteral and parenteral fish, but the lowest hepatic fat content was observed in mice 
receiving enteral fish oil (59). 
  
PNALD remains a potentially devastating disease with limited treatment options. 
Enteral fish oil is not a treatment option for all patients with PNALD, but for those 
patients with some enteral access and adequate intestinal surface area for absorption, 
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enteral fish oil supplementation may be a safe and effective adjunctive treatment. These 
initial cases have prompted us to design a multicenter, randomized, controlled 
prospective study to evaluate the use of enteral fish oil for the treatment of PNALD. 
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CHAPTER 3.    EICOSAPENTAENOIC ACID AND DOCOSAHEXAENOIC 
ACID SYNERGISTICALLY ATTENUATE BILE ACID-INDUCED 
HEPATOCELLULAR APOPTOSIS* 
 
 
Introduction 
 
Parenteral nutrition (PN)-associated liver disease (PNALD) is a common 
complication in infants receiving long-term PN. PNALD can progress from cholestasis to 
liver fibrosis, hepatic failure and death (1, 8). The etiology of PNALD is not well 
understood; it is likely multi-factorial and possibly attributed to immature bile secretion, 
inflammation, oxidative stress, infection, nutrient deficiencies, and toxic components in 
parenteral products. including lipids or amino acids (1, 24).  
 
Lipophilic bile acids, which are often increased in PNALD, are known to cause 
cellular apoptosis. Many lipophilic bile acids have been shown to induce apoptosis in 
both cellular and animal models (79-85). Apoptosis occurs by activation of death 
receptors (DR) located on the cell surface. There are six known death receptors, but the 
two that have been shown to be important in apoptosis in the liver are Fas and tumor 
necrosis factor-associated apoptosis-inducing ligand receptor 2 (TRAIL-R2) (86). 
Apoptosis occurs via different pathways depending on cell type. In type 1 cellular 
response, effector caspases (caspase-3, -6, -7) are activated by the cleavage of upstream 
caspases (79). In the type 2 cellular response, which occurs in hepatocytes, caspase 
activation requires mitochondrial pathway amplification (79). Bile acid-induced 
apoptosis is thought to occur via the Fas and TRAIL-R2 death receptors (86).  
 
Hydrophilic bile acids, primarily ursodeoxycholic acid, have been shown to 
protect hepatocytes from apoptosis by activating survival pathways (87) and have been 
used for the treatment of PNALD (88). Recent clinical research has shown reversal of 
PNALD with fish oil-based intravenous fat emulsions rich in omega-3 long-chain 
polyunsaturated fatty acid (ω3PUFA) (28, 29, 32, 89). Although, ω3PUFA 
supplementation has shown much promise in the treatment of PNALD, the mechanism of 
action is not fully understood. The aims of this study were to determine (1) if ω3PUFA 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) attenuate hepatocyte 
apoptosis associated with exposure to chenodeoxycholic acid (CDCA), a potent lipophilic 
bile acid; (2) if this attenuation is due to the down regulation of the Fas and TRAIL-R2 
receptors, thereby reducing cellular apoptosis; and (3) if EPA and DHA equally attenuate 
apoptosis associated with CDCA toxicity. 
 
 
 
 
 
*Adapted with permission. Tillman EM, Helms RA, Black DD. Eicosapentaenoic acid 
and docosahexaenoic acid synergistically attenuate bile acid-induced hepatocellular 
apoptosis. JPEN J Parenter Enteral Nutr 2012. 36(1):36-42. 
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Materials and Methods 
 
 
Cell culture 
 
HepG2 cells were obtained from the American Type Culture Collection 
(Rockville, MD) and cultured in EMEM supplemented with 10% FBS, 50 U/ml 
penicillin, and 37.5 U/ml streptomycin (growth medium). Cells were incubated at 37° C 
with 5% CO2 in a humidified incubator. Passages 25 – 45 were used for these 
experiments. 
 
 
Experimental design 
 
HepG2 cells were plated and grown to 95% confluence for all experiments, 
except for fluorescent cell staining, where cells where grown to 50% confluence. Cells 
were treated with CDCA 50 – 200 mM (Sigma-Aldrich, St. Louis, MO), ± EPA 1 - 10 
μM (Nu-check Prep, Elysian, MN), and ±  DHA 10 μM (Nu-check Prep, Elysian, MN). 
HepG2 cells were treated for 4, 8, 12, 18 and 24 hours for cell viability and caspase 
assays. Cells were treated for 0.5, 1, 1.5, 2 and 4 hour for mRNA analysis by quantitative 
real time RT-PCR.  
 
 
Cell viability 
 
Cell viability was evaluated after treating cells, as described above, followed by 
trypsinization in order to disperse cells into a 0.2% trypan blue (Sigma-Aldrich) cell 
suspension mixture. After staining, 10 μL of cell suspension was placed on a 
hemocytometer with a glass cover slip and evaluated using an inverted microscope (25x 
magnification). All cells were counted and viability was accessed. 
 
 
Nuclear staining 
 
Cells were grown on glass inserts and, once 50% confluence was achieved, cells 
were treated with CDCA ± EPA for 2 hours. Immediately following treatment, cells were 
washed with phosphate buffered saline (PBS), fixed with methanol (-10° C) for 15 
minutes, then washed with PBS. Fixed cells were then stained for 5 minutes with 
ethidium bromide (100 μg/ml) and acridine orange (100 μg/ml) (EB/AO) dye mixture 
(Sigma-Aldrich) in PBS. Following staining, cells underwent 5 washes prior to being 
mounted on glass slides using Vectashield® mounting medium and analyzed using an 
Olympus America Inc., IX50-FLA inverted reflected light fluorescence microscope 
(Lake Success, NY).  
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Caspase assay   
 
Apoptosis was evaluated using the Apo-ONE® Homogeneous Caspase-3/7 Assay 
purchased from Promega Corporation (Madison, WI) and performed according to the 
manufacturer’s instructions. HepG2 cells were treated for 4, 8, 12, 18 or 24 hours 
followed by the addition of caspase-3/7 reagent and incubation for 4 hours in the dark on 
a rocking shaker at low speed. Results were read at fluorescein 485 nm/535 nm with a 
Victor 2, Perkin-Elmer Wallace 1420 multilabel counter (Shelton, CT). 
 
 
Quantitative RT-PCR 
 
Total RNA was isolated from confluent cultures according to the manufacturer’s 
instructions with TRIzol reagent (Invitrogen, Carlsbad, CA). First-strand cDNAs were 
synthesized from 2 µg of total RNA in a 21 µL reaction volume using the SuperScript 
First-Strand Synthesis System for RT-PCR (Invitrogen) in accordance with the 
manufacturer's instructions. Quantitative PCR was performed in triplicate using the 
Model 7500 Sequence Detection System (Applied Biosystems, Foster City, CA). 
Independent PCRs were performed using the same cDNA for both the gene of interest and 
the 18S rRNA, using the SYBR Green PCR Master Mix (Applied Biosystems). Specific 
primers were designed for the genes of interest (Fas and TRAIL-R2). See Table 3-1 for 
primer sequences. A dissociation curve was generated at the end of each PCR cycle to 
verify that a single product was amplified using software provided with the 7500 
Sequence Detection System. The change in fluorescence of SYBR Green in every cycle 
was monitored by the system software, and the threshold cycle (CT) above the 
background for each reaction was calculated. The CT value of 18S rRNA was subtracted 
from that of the gene of interest to obtain a CT value. The CT value of an arbitrary 
calibrator (e.g., sample treated with ethanol as a vehicle control) was subtracted from the 
CT value of each sample to obtain a CT value. The mRNA expression level relative to 
the calibrator was expressed as 2– CT.  
 
 
Table 3-1: Cell viability demonstrated by trypan blue staining. 
 
Treatment conditions Total number of cells 
per surface area 
Viable cells per 
surface area 
% Viable 
cells 
Control 161 160 99 
EPA 10 μM 160 159 99 
CDCA 200 μM 99 77 78 
CDCA 200 μM + EPA 10 μM 105 105 100 
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Statistical analysis 
 
All data represent at least three separate and independent experiments. Data are 
provided as mean ± SEM. A one-way ANOVA was used to compare differences between 
groups and a post-hoc Tukey’s HSD (honestly significant difference) test was used to 
correct for multiple comparisons. A single-tailed P value of 0.05 was used to reject the 
null hypothesis. 
 
 
Results 
 
 
Cell viability 
 
After a 2-hour treatment with CDCA, 78% of cells were viable, whereas 100% of 
cells were viable after treatment with CDCA and EPA (Table 3-1). Although cell 
viability was 100% in cells treated with CDCA and EPA, the total cell count was only 
75% of cells exposed to medium alone. Cells treated with EPA alone resulted in similar 
viability with control and vehicle control, whereas cells treated with CDCA alone had a 
decrease in both viability and total number of dead cells. When cells were treated with 
CDCA+EPA the cell number was similar, but there were no dead cells. 
 
 
Nuclear staining 
 
Cells treated with EPA alone appear similar to control cells, with all green viable 
cells (Figure 3-1). When cells were treated with CDCA alone, not only is there free 
chromatin, which is stained orange, but cellular integrity is lost. Cells treated with 
CDCA+EPA exhibited some early stages of apoptosis, as shown by the orange staining, 
but cellular integrity was maintained. 
 
 
Caspase 3/7 activity 
 
Caspase activity was evaluated at 4, 8, 12, 18 and 24 hours (Figure 3-2). Activity 
peaked between 12 and 18 hours, therefore, a 12-hour time point was chosen for data 
reporting. A dose-dependent apoptotic effect of CDCA was observed across all time 
points, and a significant attenuation effect was observed with 1 and 10 µM EPA with 
treatment with 200 µM CDCA (Figure 3-3). Peak caspase-3/7 activity was observed with 
CDCA 200 μM. Treatment with EPA alone and DHA alone resulted in 22% and 9% 
caspase-3/7 attenuation, respectively (Figure 3-4). Caspase-3/7 activity was attenuated 
by 52 % when treated with a combination of EPA and DHA (p = 0.0034; Figure 3-4). 
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Figure 3-1: EB/AO staining and fluorescent microscopy.  
Cells stained were stained with ethidium bromide and acridine orange and viewed with 
fluorescent microscopy (1400x magnification). 
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Figure 3-2: Time course of caspase-3/7 activity.  
Data are represented as relative fluorescence units above control. Each bar represents 
mean ± SEM for three independent experiments. Statistical significance was determined 
using analysis of variance (ANOVA) with Tukey’s HSD. 
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Figure 3-3: Caspase-3/7 activity – Dose response at 12 hours.  
Data are represented by relative fluorescence units. Each bar represents mean ± SEM for 
three independent experiments. Statistical significance was determined using analysis of 
variance (ANOVA) with Tukey’s HSD. Means of data from various treatment conditions 
with different letters above the bars are significantly different from each other. 
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Figure 3-4: Caspase-3/7 activity – EPA and DHA synergy.  
Data are represented based on relative fluorescence units above control. Each bar 
represents mean ± SEM for three independent experiments. Statistical significance was 
determined using an ANOVA with Tukey’s HSD. Means of data from various treatment 
conditions with different letters above the bars are significantly different from each other. 
DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid. 
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Fas and TRAIL-R2 mRNA levels  
 
Peak Fas and TRAIL-R2 mRNA expression was observed at 0.5 hours (Figures 
3-5 and 3-6). There was a 4.7-fold increase in Fas mRNA levels when cells were 
incubated with 200 μM CDCA alone, as compared to no increase in Fas mRNA levels 
when incubated with CDCA 200 μM with the addition of EPA 1 μM, EPA 10 μM, or 5 
μM EPA + 5 μM DHA (p < 0.01; Figure 3-5). There was a 2-fold increase in TRAIL-R2 
mRNA levels when cells were incubated with CDCA 100 μM and 200 μM alone, as 
compared to no increase in TRAIL-R2 mRNA levels when incubated with both CDCA 
and EPA 1 μM, EPA 10 μM, or 5 μM EPA + 5 μM DHA (p < 0.01; Figure 3-6). No 
significant difference between treatment with EPA alone, DHA alone, or combination of 
EPA/DHA was observed in Fas or TRAIL-R2 mRNA expression. Interestingly, EPA and 
DHA separately appeared to induce a low level of both Fas and TRAIL-R2 mRNA when 
no CDCA was present. However, this effect was not observed with the combination of 
the two fatty acids with or without CDCA (Figures 3-5 and 3-6). 
 
Fas and TRAIL-R2 mRNA levels were measured by quantitative RT-PCR. 
Values are based on fold change relative to the vehicle control. Statistical significance 
was determined using an ANOVA with Tukey’s HSD. Each bar represents mean + SEM 
for data from three culture wells. Statistical significance was determined using an 
ANOVA with Tukey’s HSD. Means of data from various treatment conditions with 
different letters above the bars are significantly different from each other at p < 0.05 by 
ANOVA. Those sharing the same letter or no letter are not significantly different from 
each other. 
 
 
Discussion 
 
The results from this study show for the first time that the ω3PUFA EPA and 
DHA significantly attenuate CDCA-induced apoptosis in cultured hepatocytes. The 
results demonstrate: 1) CDCA dose-dependent induction of apoptosis documented by 
caspase 3/7 activity and Fas and TRAIL-R2 mRNA expression; 2) attenuation of CDCA-
induced apoptosis via caspase 3/7 by EPA; 3) synergistic attenuation of CDCA-induced 
apoptosis by the combination of EPA and DHA as documented by caspase-3/7 activity, 
but not Fas or TRAIL-R2 mRNA expression.  
 
HepG2 cells treated with CDCA for 0.5 hour exhibited increased expression of 
both Fas and TRAIL-R2 mRNA in a dose-dependent manner. This up-regulation of 
expression of Fas and TRAIL-R2 mRNA with CDCA treatment was attenuated when 
cells were treated with EPA, DHA, or a combination of both EPA and DHA. Lipophilic 
bile acids such as deoxycholic acid (DCA), CDCA, and the glycine-conjugated form of 
deoxycholic acid (GDCA) have been previously shown to up-regulate expression of Fas 
and TRAIL-R2 in liver cells (79, 86, 90). Merino et al. (91) suggested that TRAIL-R3 
and TRAIL-R4 inhibit apoptosis by acting as decoy receptors that bind TRAIL, but do 
not trigger activation of initiator caspases to lead to apoptosis.(91) These receptors are  
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Figure 3-5: Fas mRNA levels. 
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Figure 3-6: TRAIL-R2 mRNA levels. 
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found in the cell membrane within lipid rafts. The fluidity of ω3PUFA and the rigidity of 
cholesterol can result in incompatibility and can greatly alter the composition of lipid 
rafts (92, 93). Treatment with ω3PUFA may attenuate Fas- and TRAIL-R2-induced 
apoptosis by incorporation of ω3PUFA into membranes, causing fluidity or other 
alterations in lipid rafts and resulting in changes in death receptor function. However, 
such a mechanism involving direct modulation of protein function would not account for 
the pre-translational regulation of Fas and TRAIL-R2 mRNA expression that we 
observed.  
 
It is established that composition and levels of free fatty acids (FFA) can 
significantly alter cell survival pathways. Free fatty acids have been shown to inhibit 
serum-starved apoptosis in a murine cell model via GPR120 (94). In these experiments 
both saturated and unsaturated FFA enhanced cell survival, but linolenic acid, palmitoleic 
acid, and DHA had the most potent effects on cell survival (95). GPR120 has recently 
been shown to be a receptor or sensor for ω3PUFA, mediating regulation of inflammation 
(96). GPR 120 inhibits both Toll-like receptors (TLR) 2/3/4 and the TNF-α cascade, 
suggesting that IKKβ and JNK may be iatrical transcription factors affected by GPR120 
binding (96). NFκB, IKKβ, and JNK have all been shown to play a role in the up-
regulation of death receptors in the presence of noxious stimuli (79, 97). The up-
regulation of Fas and TRAIL-R2 mRNA by CDCA and the attenuation of this increase by 
ω3PUFA that we observed may also be independent of the aforementioned transcription 
factors and may result from regulation of mRNA stability. Nakata et al. (98) have 
previously demonstrated up-regulation of TRAIL-R2 mRNA independent of transcription 
factors when treated human cancer cells were treated with 15-deoxy-delta(12,14)-
prostaglandin J(2), and apoptosis was attenuated in the presence of a double-stranded 
small interfering RNA (siRNA) targeting the DR5 gene. Small interfering RNA duplexes, 
as well as micro-RNAs, have been studied for their roles in interference with expression 
of Fas, TRAIL-R2, and other pro-apoptotic and anti-apoptotic genes (99-101). 
 
We observed a synergistic attenuation of CDCA-induced apoptosis via caspase-
3/7 with a combination of EPA and DHA, yet Fas and TRAIL-R2 mRNA expression was 
not significantly different from that observed with EPA alone, DHA alone, or a 1:1 molar 
ratio of EPA to DHA. This discrepancy may suggest that DHA and EPA are involved in 
multiple pathways of apoptosis attenuation. This is not surprising because EPA and DHA 
are structurally different and have been shown to have varying effects on cellular 
functions. For example, the additional double bond in DHA compared to EPA creates an 
increased number of bends in the acyl chain that cause shortening. Length and saturation 
of hydrocarbon chains can greatly affect mitochondrial membrane permeability (102). As 
discussed previously, hepatocyte apoptosis is mediated via the mitochondria, and changes 
in mitochondrial membrane permeability could influence hepatocellular apoptosis. The 
EPA and DHA synergy in attenuation of CDCA-induced apoptosis that we observed may 
represent the end result of ω3PUFA functioning via multiple mechanisms, including 
alteration of cell membrane fluidity, receptor binding, transcriptional regulation, and non-
transcriptional regulation of RNA levels, resulting in the anti-apoptotic effects. To our 
knowledge, there are no published studies illustrating a synergistic attenuation of 
apoptosis by the combination of EPA and DHA.  
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Although we have shown differences in both Fas and TRAIL-R2 expression in 
HepG2 cells treated with CDCA in the presence and absence of EPA, there may also be 
other mechanisms that are responsible for some of the protective effects of ω3PUFA in 
the face of bile acid-induced cell injury. Additional studies are underway in our 
laboratory to clearly define the precise mechanism(s) of action of ω3PUFA in reversing 
bile acid-induced cell injury. Collectively, our findings clearly demonstrate the 
attenuation of CDCA-induced hepatocellular apoptosis by ω3PUFA. With CDCA-
induced apoptosis serving as a model for cholestatic liver disease, these results support 
the therapeutic use of fish oil rich in ω3PUFA for the treatment of PNALD. 
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CHAPTER 4.    ATTENUATION OF BILE ACID-INDUCED 
HEPATOCELLULAR APOPTOSIS BY OMEGA-3 LONG-CHAIN 
POLYUNSATURATED FATTY ACIDS VIA DEATH RECEPTORS 
 
 
Introduction 
 
Parenteral nutrition (PN)-associated liver disease (PNALD) occurs in patients 
receiving long-term PN and may progress from cholestasis to liver cirrhosis, hepatic 
failure and death. Human studies have shown omega-3 long chain polyunsaturated fatty 
acids (ω3PUFA) to be beneficial in attenuating PNALD (103). Although ω3PUFAs seem 
to be effective in attenuating disease, the mechanism is unknown. 
 
Lipophilic bile acids, which are often increased in cholestasis associated with 
PNALD, are known to cause cellular injury and may trigger pro-inflammatory cytokine 
release by both hepatocytes and Kupffer cells. These cytokines are potent inhibitors of 
hepatobiliary transporter gene expression, which may be responsible for impaired bile 
secretion, resulting in conjugated hyperbilirubinemia and cholestasis, leading to 
accumulation of hepatotoxic bile acids (104, 105). Lipophilic bile acids, such as 
chenodeoxycholic acid (CDCA), have been shown to induce apoptosis in both cellular 
and animal models (79-85). Apoptosis occurs by activation of death receptors (DR) 
located on the cell surface. There are six known death receptors, but the two that have 
been shown to be most important in apoptosis in the liver are Fas and tumor necrosis 
factor-associated apoptosis-inducing ligand receptor 2 (TRAIL-R2) (86). Apoptosis 
occurs via different pathways depending on cell type. In type 1 cellular response, effector 
caspases (caspase-3,6,7) are activated by the cleavage of upstream caspases (79). In type 
2 cellular response, which occurs in hepatocytes, caspase activation requires 
mitochondrial pathway amplification (79). Bile acid-induced apoptosis is thought to 
occur predominantly via the Fas and TRAIL-R2 death receptors (86), although bile acids 
may also act directly on the mitochondria and increase permeability, thereby increasing 
the release of cytochrome c (106). In our in vitro model of PNALD, we previously 
reported that apoptosis was associated with increased mRNA expression of death 
receptors Fas and TRAIL-R2 (107). The aims of this study were to: 1) determine whether 
hepatocellular apoptosis induced by the hydrophobic bile acid CDCA occurs solely via 
the death receptors Fas and TRAIL-R2 in an in vitro model; 2) determine specific 
apoptotic pathways involved in the attenuation of PNALD by ω3PUFA in an in vitro 
model; and 3) determine if Fas and TRAIL-R2 are involved in the attenuation of PNALD 
by ω3PUFA in an in vivo model. 
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Materials and Methods 
 
 
Cell culture 
 
HepG2 cells were obtained from the American Type Culture Collection 
(Rockville, MD) and cultured in Eagle’s Minimum Essential Medium (EMEM) 
supplemented with 10% FBS, 50 U/ml penicillin, and 37.5 U/ml streptomycin (growth 
medium). Cells were incubated at 37° C with 5% CO2 in a humidified incubator. 
Passages 10 – 32 were used for these experiments. 
 
 
Experimental design for cell culture studies 
 
HepG2 cells were plated and grown to 95% confluence for all experiments. Cells 
were treated with CDCA 200 mM (Sigma-Aldrich, St. Louis, MO), ± EPA 5 μM (Nu-
check Prep, Elysian, MN), and ± DHA 5 μM (Nu-check Prep). Controls included cells 
incubated with vehicle alone (EtOH). HepG2 cells were treated for 12 hours for caspase 
assays. Cells were treated for 0.5 hour for mRNA analysis by quantitative real time RT-
PCR. Time points were determined by previous studies (107). 
 
 
Apoptosis array and quantitative RT-PCR 
 
Total RNA was isolated from confluent cultures according to the manufacturer’s 
instructions with TRIzol reagent (Invitrogen, Carlsbad, CA). First-strand cDNAs were 
synthesized from 2 µg of total RNA in a 21 µL reaction volume using the SuperScript 
First-Strand Synthesis System for RT-PCR (Invitrogen, Carlsbad, CA) in accordance with 
the manufacturer's instructions. Quantitative PCR was performed in triplicate using the 
Model 7500 Sequence Detection System (Applied Biosystems, Foster City, CA). 
Independent PCRs were performed using the same cDNA for both the gene of interest and 
the 18S rRNA, using the SYBR Green PCR Master Mix (Applied Biosystems). Eighty-
four key genes involved in apoptosis were evaluated with The Human Apoptosis RT² 
Profiler PCR Array profiles (SABiosciences, Qiagen, Valencia, CA) using quantitative 
real-time RT-PCR.  
 
 
Antibody treatment 
 
Cells were treated with 200 μM CDCA, CDCA + Fas antibody 300 ng/mL 
(Abcam, Cambridge, MA), CDCA + TRAIL-R2 antibody 300 ng/mL (Abcam), and 
CDCA + Fas antibody + TRAIL-R2 antibody. Controls included cells incubated with 
vehicle alone (EtOH). Apoptosis was evaluated using the Apo-ONE® Homogeneous 
Caspase-3/7 Assay.  
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Caspase assay 
 
Cultured HepG2 cells were treated with 200 μM CDCA, CDCA + Fas antibody, 
CDCA + TRAIL-R2 antibody, and CDCA + Fas antibody + TRAIL-R2 antibody. 
Apoptosis was evaluated using the Apo-ONE® Homogeneous Caspase-3/7 Assay 
purchased from Promega Corporation (Madison, WI) and performed according to the 
manufacturer’s instructions. HepG2 cells were treated for 12 hours followed by the 
addition of caspase-3/7 reagent and incubation for 4 hours in the dark on a rocking shaker 
at low speed. Results were read at fluorescein 485nm/535nm with a Victor 2, Perkin-
Elmer Wallace 1420 multilabel counter (Shelton, CT). 
 
 
Murine model 
 
C57BL/6 wild-type adult male mice (8-10 weeks old; The Jackson Laboratory, 
Bar Harbor, ME) were exposed ad libitum to 2.5% dextran sulfate sodium (DSS) in 
drinking water for 4 days. Mice then received regular drinking water for 24 hours before 
placement of a central venous catheter (CVC; Silastic tubing, 0.012 inches internal 
diameter; Dow Corning) into the right jugular vein. The proximal end of the CVC was 
tunneled subcutaneously, exited between the shoulder blades, and connected to an 
infusion pump (Harvard Apparatus, Holliston, MA). Mice were placed in a rubber 
harness (Instech Laboratories, Plymouth Meeting, PA) and recovered from surgery for 24 
hours with intravenous normal saline (NS) infusion at a rate of 0.23 mL/hour and given 
ad libitum access to chow and water. After 24 hours, mice were continuously infused for 
7 or 28 days with PN (PN7d/DSS and PN28d/DSS, respectively) at a rate of 0.29 
mL/hour, providing a caloric intake of 8.4 kcal/24 hours, as previously described (108). 
All PN-infused mice had access to water ad libitum but not to chow. All mice were 
individually housed in metabolic cages. Blood was collected from the retro-orbital 
plexus. Serum was analyzed by the University of Colorado Hospital Clinical Chemistry 
Laboratory for aspartate aminotransferase (AST), alanine aminotransferase (ALT), and 
total bilirubin levels. Total bile acids (TBA) were analyzed using a total bile acid 
detection kit (Diazyme Laboratories, Poway, CA). All animals were treated humanely, 
and all animal procedures were approved by the Institutional Animal Care and Use 
Committee. 
 
 
Tissue RNA isolation and quantitative gene expression analysis 
 
RNA was extracted using TRIzol (Invitrogen), DNAse-treated (Ambion, Austin, 
TX) and reverse-transcribed with iScript (BioRad, Hercules, CA). Gene expression was 
analyzed by qRT-PCR on an Applied Biosystems 7300 cycler using commercially 
available TaqMan gene expression assays (Applied Biosystems). Data are expressed as 
normalized gene expression relative to chow mice or NS/DSS-treated mice using the Δ/Δ 
Ct method. RNA was extracted, prepared, and analyzed from whole liver tissue as 
previously described (108). 
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Statistical analysis 
 
All data represent at least three separate and independent experiments. Data are 
provided as mean ± SEM. A one-way ANOVA was used to compare differences between 
groups and a post-hoc Tukey’s HSD test was used to correct for multiple comparisons. A 
single-tailed p value of 0.05 was used to reject the null hypothesis. 
 
 
Results 
 
 
Apoptosis focused array 
 
There was a 286-fold increase in Fas ligand (FasL) mRNA levels when cells were 
incubated with CDCA alone, as compared to 9.8-fold increase in FasL mRNA levels 
when incubated with CDCA with the addition of ω3PUFA (p < 0.01). There was a 1.4-
fold increase in Fas with CDCA alone, and a 2.0-fold decrease when treated with 
CDCA+ ω3PUFA. There was a 38-fold increase in FADD mRNA levels when cells were 
incubated with CDCA alone, as compared to a 3.8-fold increase in FADD mRNA levels 
when incubated with both CDCA+ ω3PUFA (p < 0.01). There was a 142-fold increase in 
caspase 8 (CASP8) mRNA levels when cells were incubated with CDCA alone, as 
compared to a 44.8-fold increase in CASP8 mRNA levels when incubated with CDCA+ 
ω3PUFA (p < 0.01). Interesting, CASP8- and FADD-like apoptosis regulator (CFLAR) 
was increased 1.5-fold when cells were incubated with CDCA alone, as compared to a 
2.4-fold increase in CFLAR mRNA levels when incubated with CDCA+ ω3PUFA (p < 
0.01; Figures 4-1 and 4-2).  
 
 
Apoptosis independent of Fas and TRAIL-R2 
 
Treatment of HepG2 cells with 200 μM CDCA resulted in peak caspase activity at 
12 hours (Figure 4-3). Incubation with an antibody to Fas resulted in attenuation of 
caspase-3/7 by 44%. When cells were incubated with an antibody to TRAIL-R2, caspase-
3/7 activity was attenuated by 9%. The addition of antibodies to both Fas and TRAIL-R2 
resulted in 44% attenuation of caspase-3/7. 
 
 
 
 
 
Figure 4-1: Heat map of apoptosis focused array. 
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Figure 4-2: Summary of apoptosis focused array. 
 
 
 
 
 
 
 
Figure 4-3: Caspase-3/7 activity. 
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Liver injury in mice exposed to PN+DSS 
 
Mice were pretreated with DSS and randomized into two groups that were infused 
with either PN (PN7d/DSS mice; n = 30) or NS (NS/DSS mice: n = 20) for 7 days. 
PN7d/DSS treatment resulted in significantly elevated AST (≈4-fold; p = 0.0006), ALT 
(≈4 fold; p = 0.0008), and total bilirubin (≈2-fold; p = 0.0137) levels compared with 
NS/DSS, DSS (n = 9), DSS+8d chow (n = 6), and untreated chow mice (n = 20; Figure 
4-4). We next tested whether infusion with PN by itself would promote liver injury. PN 
infusion for 7 days by itself did not cause significant liver injury as measured by AST, 
ALT, and bilirubin levels in PN mice (n = 10) compared with NS (n = 12) or untreated 
chow mice (n = 20; p > 0.05). Infusion of PN in DSS-pretreated mice was performed for 
28 days (PN28d/DSS mice; n = 5). AST and bilirubin levels remained elevated and were 
comparable to those in PN7d/DSS mice (n = 30), while ALT levels were even further 
increased after 28 days of PN (Figure 4-4). 
 
 
Death receptor expression in PN-fed mice 
 
Expression of Fas was increased 1.5-fold in mice pretreated with DSS followed 
by 7 days of PN. In mice that received DSS pretreatment followed by 28 days of PN, Fas 
was increased 2-fold (Figure 4-5). TRAIL mRNA expression was increased 1.25-fold 
over control in mice fed standard chow, decreased 0.75-fold with DSS and 7 days of PN, 
and decreased 0.5-fold with DSS and 28 days of PN (Figure 4-6). Interestingly, there 
was no change in Fas-L or TRAIL-R2 (data not shown). 
 
 
Discussion 
 
The results from this study show that apoptosis associated with PNALD occurs 
via the death receptor Fas, but also independent of Fas. The results demonstrate that: 1) 
the attenuation of bile acid-induced apoptosis by ω3PUFA in an in vitro model occurs 
independent of death receptors; 2) hepatocellular apoptosis induced by the hydrophobic 
bile acid CDCA occurs mainly via the death receptors Fas and to a lesser extent TRAIL- 
 
 
 
 
 
Figure 4-4: Liver function tests in mice exposed to PN+DSS. 
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Figure 4-5: Fas expression in mice treated with PN+DSS. 
 
 
 
 
 
 
 
Figure 4-6: TRAIL expression in mice treated with PN+DSS. 
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R2 in an in vitro model; and 3) the death receptor Fas and TRAIL are involved in 
PNALD in an in vivo model. 
 
Treatment with bile acid alone increased gene expression of FasL, Fas, FADD, 
and CASP8. Treatment with CDCA and the addition of ω3PUFA resulted in less fold-
increase in each of these apoptotic mediators. This suggests that attenuation of bile acid-
induced apoptosis occurs via a decrease in Fas ligand, thereby reducing binding to Fas 
and the activation of FADD and CASP8 necessary for mitochondrial amplification to 
trigger the release of cytochrome c and the apoptosome formation. These results suggest 
that the attenuation of bile acid induced apoptosis occurs via Fas-dependent pathways 
(Figure 4-7). 
 
Bile acid-induced apoptosis has been shown to occur that is both dependent on 
and independently of hepatic death receptors (79). However, the effect of fatty acids on 
bile acid-induced apoptosis is not well defined. In a model of NAFLD, ω9PUFA (oleic 
acid), was shown to increase glycochenodeoxycholic-acid induced apoptosis and increase 
transcription of pro-inflammatory cytokines (109). Free fatty acids have also been shown 
to enhance apoptosis via TRAIL, but not via Fas (110). Conversely, free fatty acids have 
been shown to bind to GPR40 and GPR120 and inhibit serum deprivation-induced 
apoptosis in a mouse enteroendocrine cell line (94). Additionally, free fatty acids have 
been shown to increase cholecystokinin production via GPR120 (111), which could also 
play a role in the attenuation of liver injury. 
 
Here we have shown that bile acid-induced hepatocellular apoptosis occurs 
predominately via Fas and to a lesser extent via TRAIL-R2. These data confirm our 
earlier mRNA findings (107). Although there was a 44% attenuation of caspase-3/7 
activity when both Fas and TRAIL-R2 were blocked with corresponding antibodies, these 
data suggest that bile acid-induced apoptosis also occurs via mechanisms that are 
independent of the death receptors Fas and TRAIL-R2. Yang et al. has suggested that bile 
acid induced apoptosis occurs partially via activation of the novel G protein-coupled cell-
surface bile acid receptor TGR5, which activates JNK and leads to formation of a 
complex between JNK and caspase-8 (81). 
 
We have previously shown that both Fas and TRAIL-R2 are increased in an in 
vitro model of PNALD (107); this had not yet been shown in an in vivo model. Here we 
have shown that the expression of both Fas and TNFS10 were altered in an in vivo model 
of PNALD. Fas expression increased with duration of PN treatment. This also 
corresponds to increased AST, ALT, and total bile acids, indicating that Fas-dependent 
apoptosis is directly related to the severity of PNALD. Expression of the ligand TRAIL 
decreased with exposure to PN, which could be explained by increased binding of TRAIL 
to the TRAIL-R2 death receptor. Although this is the first report of death receptor-
dependent apoptosis associated with PNALD, this is not the first report of apoptosis 
associated with PNALD. Hong et al. suggested that PNALD in an infant rabbit model is 
associated with mitochondria-initiated apoptosis. After 10 days of PN, rabbits had 
increased hepatic superoxide dismutase activity and a significant increase in cytochrome  
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Figure 4-7: Proposed mechanism of Fas-dependent apoptosis. 
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c release from the mitochondria, and increased caspase-3 activity, resulting in apoptosis 
(112). 
 
Although these data suggest that bile acid-induced apoptosis primarily occurs via 
Fas-dependent pathways in HepG2 cells treated with CDCA in the presence and absence 
of EPA, there may also be other mechanisms that are responsible for some of the 
protective effects of ω3PUFA in the face of bile acid-induced cell injury. The animal data 
reported here confirm the in vitro findings that death receptors play an important role in 
apoptosis associated with PNALD. Additional studies are underway in our laboratory to 
clearly define the precise mechanism(s) of action of ω3PUFA in reversing bile acid-
induced cell injury. Collectively, our findings clearly demonstrate the attenuation of 
CDCA-induced hepatocellular apoptosis by ω3PUFA. With CDCA-induced apoptosis 
serving as a model for cholestatic liver disease and an in vivo mouse model, these results 
support the therapeutic use of fish oil rich in ω3PUFA for the treatment of PNALD. 
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CHAPTER 5.    BILE ACID-INDUCED APOPTOSIS AND INFLAMMATION 
ARE ATTENUATED BY OMEGA-3 LONG-CHAIN POLYUNSATURATED 
FATTY ACIDS IN A MACROPHAGE MODEL 
 
 
Background 
 
Parenteral nutrition (PN)-associated liver disease (PNALD) is one of the most 
alarming complications of long-term PN. PNALD is a progressive disease that can lead to 
liver failure and death. In many cases, children require liver and small bowel 
transplantation, prolonged hospitalization and home care. PN is associated with a loss of 
epithelial barrier function, which can lead to intestinal dysfunction and the transit of 
luminal toxins [lipopolysaccharide (LPS) and tumor necrosis factor (TNF)] into the host 
(113). When these toxins migrate from the leaky gut into the portal circulation they 
activate Kupffer cells that act as macrophages in the liver and secrete pro-inflammatory 
cytokines. This is thought to play a role in the development of PNALD. Investigators 
have shown that activation of Kupffer cells is necessary to evoke parenchymal liver 
injury and that attenuation of Kupffer cell-mediated response in turn attenuates liver 
injury.  
 
Studies have shown improvements in PNALD with omega-3 long-chain 
polyunsaturated fatty acids (ω3PUFA) containing eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA). Anti-inflammatory and anti-apoptotic effects have been 
attributed to ω3PUFA. The purpose of this study was to examine 1) anti-inflammatory 
and anti-apoptotic effects of ω3PUFA on macrophage response to bile acid-induced and 
LPS cellular injury, and 2) the effects of macrophage activation on hepatocytes. 
 
 
Materials and Methods 
 
 
Cell culture 
 
Human acute monocytic leukemia cells (THP-1) were obtained from American 
Type Culture Collection (Rockville, MD) and cultured in RPMI-1640 medium 
supplemented with 10% FBS, 50 U/ml penicillin and 37.5 U/ml streptomycin. THP-1 
cells were used as a sergeant for the Kupffer cells. THP-1 cells were plated and 
differentiated with phorbol 12-myristate 13-acetate (PMA) to a final concentration of 5 
ng/mL for 48 hr prior to being treated with conditions described below. 
 
HepG2 cells were obtained from the American Type Culture Collection and 
cultured in Eagle’s Minimum Essential Medium (EMEM) supplemented with 10% FBS, 
50 U/ml penicillin and 37.5 U/ml streptomycin. All cells were incubated at 37° C with 
5% CO2 in a humidified incubator. Passages 10 – 32 were used for these experiments. 
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Cell treatment conditions  
 
THP-1 cells were treated with 200 µmol/L of chenodeoxycholic acid (CDCA) ± 
ω3PUFA (5 µM EPA and 5 µM DHA). Salmanilla LPS 20 µmol/L, ethanol (EtOH), 
ω3PUFA alone, and staurosporine 10 µmol/L served as controls. After treatment, cellular 
supernatants and cells were collected for ELISA assays and/or caspase-3/7 reagents. 
  
THP-1 cells were treated with LPS 20 ng/mL for 30 minutes. After treatment, the 
supernatant was withdrawn, added to confluent HepG2 cells and allowed to incubate for 
one hour. RNA was isolated for RT-PCR and caspase-3/7 was evaluated. 
 
 
Caspase activity   
 
Apoptosis was evaluated using the Apo-ONE® Homogeneous Caspase-3/7 Assay 
purchased from Promega Corporation (Madison, WI) and performed according to the 
manufacturer’s instructions. HepG2 cells were treated for 12 hours followed by the 
addition of caspase-3/7 reagent and incubation for 4 hours in the dark on a rocking shaker 
at low speed. Results were read at fluorescein 485nm/535nm with a Victor 2, Perkin-
Elmer Wallace 1420 multilabel counter (Shelton, CT). 
 
 
Cytokine evaluation 
 
Cytokines (IL-1β, IL-6, TNF-α) were measured in both supernatant and nuclear 
protein using enzyme-linked immunosorbent assays (ELISAs).  
 
 
Quantitative RT-PCR 
  
Total RNA was isolated from confluent cultures according to the manufacturer’s 
instructions with TRIzol reagent (Invitrogen, Carlsbad, CA). First-strand cDNAs were 
synthesized from 2 µg of total RNA in a 21 µL reaction volume using the SuperScript 
First-Strand Synthesis System for RT-PCR (Invitrogen, Carlsbad, CA) in accordance with 
the manufacturer's instructions. Quantitative PCR was performed in triplicate using the 
Model 7500 Sequence Detection System (Applied Biosystems, Foster City, CA). 
Independent PCRs were performed using the same cDNA for both the gene of interest and 
the 18S rRNA, using the SYBR Green PCR Master Mix (Applied Biosystems). 
 
 
Statistical analysis 
 
All data represent at least three separate and independent experiments. Data are 
provided as mean ± SEM. A one-way ANOVA was used to compare differences between 
groups and a post-hoc Tukey’s HSD test was used to correct for multiple comparisons. A 
single-tailed p value of 0.05 was used to reject the null hypothesis. 
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Results 
 
 
Caspase-3/7 evaluation in THP-1 cells 
 
We first performed a time course study to determine the optimal treatment time 
for THP-1 cells. Cells were treated for 15 min, 30 min, 45 min and 1 hour. We 
determined that peak caspase-3/7 activity resulted within 15 minutes of treatment (Figure 
5-1). Treatment of THP-1 cells with CDCA and ω3PUFA resulted in a 26% decrease of 
apoptosis in comparison to CDCA alone (p < 0.01; Figure 5-2).  
 
 
Cytokine production 
 
Both TNF-α and IL-1β production decreased by 16% (p = 0.038) and 19% (p = 
0.03), respectively (Figures 5-3 and 5-4). There was no change in IL-6 concentration 
with either treatment group (Figure 5-5).  
 
When HepG2 cells were treated with medium containing cytokines (IL-1β, IL6 
and TNF-α) excreted from THP-1 cells exposed to lipophilic bile acid, there was a 2-fold 
increase in NF-κB. Treatment with endotoxin alone or bile acid and endotoxin did not 
result in a significant increase in NF-κB expression over control (Figure 5-6). 
 
 
Discussion 
 
The results from this study show that apoptosis and inflammation associated with 
PNALD is not limited to hepatocyte injury and may also involve the activation of 
Kupffer cells in the liver. The results demonstrate: 1) ω3PUFAs attenuate bile acid-
induced apoptosis in a macrophage model; 2) ω3PUFA attenuated inflammation via IL-
1β and TNF-α in a macrophage model; and 3) macrophage stimulation with lipophilic 
bile acid and endotoxin increased NFκ-B expression in hepatocytes. 
 
THP-1 cells treated with CDCA for 0.5 hour exhibited increased expression of 
secretion of IL-1β and TNF-α. This inflammatory response observed with CDCA 
treatment was attenuated when cells were treated with combination of both EPA and 
DHA. ω3PUFAs are known for having important anti-inflammatory effects and have 
been used for the treatment of many inflammatory diseases, including cardiovascular 
disease, arthritis, asthma, sepsis, autoimmune disease and malignancy (57). 
 
The anti-inflammatory role of ω3PUFA is well known. The ability of ω3PUFA to 
attenuated liver injury has been studied, but these specific mechanisms are not fully 
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Figure 5-1: Time course of caspase-3/7 activity in THP-1 cells. 
 
 
 
 
 
 
Figure 5-2: Caspase-3/7 activity in THP-1 cells treated for 15 minutes. 
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Figure 5-3: TNF-α production in THP-1 cells. 
 
 
 
 
 
 
 
Figure 5-4: IL-1β production in THP-1 cells. 
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Figure 5-5: IL-6 production in THP-1 cells.  
 
 
 
 
 
 
 
Figure 5-6: NF-κB expression in HepG2 cells stimulated with conditioned 
medium from THP-1 cells. 
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elucidated (69, 108, 114). Specifically, there is little known about the role of ω3PUFA in 
the attenuation of Kupffer cell activation. Kupffer cell activation in the progression of 
liver injury has been studied in many different types of liver diseases (115, 116). Kupffer 
cells can be activated by endotoxin, reactive oxygen species, bile acids, or other cellular 
toxins (117-120). Regardless of the stimulus the activation of the Kupffer cell leads to a 
cellular inflammatory response which may activate apoptosis (121). Kitagawa et al. has 
shown that branched-chain amino acids have a role in the attenuation of Kupffer cell 
activation in a rate model of ischemia-reperfusion-induced liver injury (122). 
 
Apoptosis in THP-1 cells was induced by CDCA alone and attenuated by co-
incubation of CDCA and ω3PUFA. The attenuation of cellular injury in this model of 
Kupffer cells provides the basis on which to determine the interaction of Kupffer cells 
and hepatocytes in order to understand the role of ω3PUFA in the treatment of PNALD.  
 
When THP-1 cells were stimulated with CDCA and then the medium containing 
cytokines (IL-1β, IL6, and TNF-α) was added to HepG2 cells, we observed a 2-fold 
increase in NF-κB. This model of treating THP-1 cells with various stimuli and applying 
conditioned medium to HepG2 cells will allow us to evaluate the mechanisms of 
hepatotoxicity related to macrophage activation. 
 
Additional studies are underway in our laboratory to clearly define the precise 
mechanism(s) of action of ω3PUFA in reversing bile acid and endotoxin-induced cell 
injury, as well as the interplay between parenchymal and non-parenchymal cells. 
Collectively, our findings clearly demonstrate the attenuation of CDCA- and LPS-
induced inflammation and apoptosis by ω3PUFA. With this serving as a model for 
cholestatic liver disease, these results support the therapeutic use of fish oil rich in 
ω3PUFA for the treatment of PNALD. 
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CHAPTER 6.    PPAR-Α IN THE ATTENUATION OF PARENTERAL 
NUTRITION-ASSOCIATED LIVER DISEASE BY OMEGA-3 LONG-CHAIN 
POLYUNSATURATED FATTY ACIDS IN AN IN VITRO CELLULAR 
MODEL 
 
 
Background 
 
Peroxisome proliferator-activated receptor alpha (PPARα) is a nuclear receptor 
transcription factor that regulates lipid metabolism. When bound to a ligand, PPARα 
forms a heterodimer with retinoid X receptor (RXR) that binds to the peroxisome 
proliferator response element (PPRE) in the promoter region of target genes and 
modulates expression. Activation of PPARα inhibits NFκB activation, thereby repressing 
inflammation (123, 124). Hepatic nuclear receptor RXR has also been shown to be 
important in hepatic responses to inflammation (125). Alternatively, NFκB activation 
increases expression of anti-apoptotic genes, such as the caspase-8 inhibitor c-FLIP, 
which could lead to resistance to Fas ligand and/or TNF-dependent apoptosis (126). 
Previous studies have shown ω3PUFA to be a PPARα agonist, thereby inhibiting NFκB 
activation (124). In studies in PPARα null mouse hepatocytes treated with nafenopin (a 
peroxisome proliferator), apoptosis was not suppressed, although treatment with TNFα 
was able to suppress apoptosis in PPARα null hepatocytes (127). These studies 
demonstrated that PPARα mediates hepatocyte apoptosis, yet high concentrations of 
TNFα can modulate this response (127). This result suggests that PPARα inhibition of 
NFκB may play an important role in the overall cellular innate immune response and cell 
survival. The pathways affected by PPARα and NFκB are complex and, in some cases, 
seemingly contradictory. The suppression of pro-inflammatory cytokine transcription by 
PPARα via NFκB would support our hypothesis, but the NFκB-mediated suppression of 
anti-apoptotic pathways would suggest that ω3PUFA activation of PPARα could result in 
increased apoptosis. These contradictory effects of NFκB on apoptosis have perplexed 
investigators studying interferon-mediated activation of NFκB, which results in anti-viral 
and pro-apoptotic activity. There is also evidence that micro-RNAs may have an 
important role in this complex signaling pathway (128). Finally, PPARα is known to 
inhibit apoptosis via NFκB-independent pathways, such as up-regulation of the 14-3-3 
proteins (129). 
 
Omega-3 PUFA have been shown to be anti-inflammatory and 
immunomodulatory and to attenuate cellular injury (59, 65, 69, 130-132). Interestingly, 
ω3PUFA have been shown to paradoxically both inhibit apoptosis and sensitize cells to 
apoptosis (109, 110, 133, 134). It is established that the composition and levels of free 
fatty acids (FFA) can significantly alter cell survival pathways. Free fatty acids have been 
shown to inhibit serum-starved apoptosis in a murine cell model via the G-coupled 
protein receptor, GPR120 (94). In these experiments both saturated and unsaturated FFA 
enhanced cell survival, but linolenic acid, palmitoleic acid, and DHA had the most potent 
effects on cell survival (95). GPR120 has recently been shown to be a receptor or sensor 
for ω3PUFA, mediating regulation of inflammation, and inhibits both Toll-like receptor 
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(TLR) 2/3/4 and TNF-α cascades (96). NFκB and JNK have both been shown to play a 
role in the up-regulation of death receptors in the presence of noxious stimuli (79, 97). 
 
The objective of this study is to determine if ω3PUFA attenuate PNALD-induced 
apoptosis and inflammation via PPARα. The rationale for this is that these studies will 
elucidate a possible pathway by which ω3PUFA attenuate hepatocellular injury by 
focusing on the transcription factor PPARα, for which ω3PUFA are known ligands.  
 
 
Materials and Methods 
 
 
Cell culture 
 
Cell culture experiments were performed using HepG2 cells obtained from the 
American Type Culture Collection (Rockville, MD). Cell culture experiments used 
standard medium, incubation conditions, and passages according to the supplier’s 
instructions.  
 
 
Cell treatment conditions 
 
HepG2 cells were treated with CDCA 200 μM (Sigma-Aldrich, St. Louis, MO) 
with and without the addition of EPA and DHA (Sigma-Aldrich). 
 
 
PPARα activation 
 
Activation of PPARα was evaluated by isolation of nuclear protein after 4-hr 
treatment and measured by assessing transcription factor activity in a non-radioactive, 
sensitive ELISA method for detecting PPARα DNA binding activity in nuclear extracts. 
 
 
PPARα expression 
 
HepG2 cells treated with chenodeoxycholic acid 200 μM (CDCA) ± ω3PUFA 
(EPA 5 μM + DHA 5 μM) for 0.5 hours and expression of PPARα, liver X receptor 
(LXR), and retinoid X receptor (RXR) were evaluated by RT-PCR using an ABI 7500 
Sequence Detector and SYBR Green PCR Master Mix according to the manufacturer's 
instructions. Levels of mRNA were normalized to 18s ribosomal RNA quantified 
simultaneously to the selected mediators in a multiplex RT-PCR reaction. All samples 
were analyzed in triplicate 
 
 
 51 
 
 
Gene-specific knockdown using RNAi technique 
 
HepG2 cells were transfected with non-target siRNA or human PPARα-specific 
siRNA using DharmaFECT transfection reagents (Dharmacon, Lafayette, CO) according 
to the manufacturer's protocol. To determine transfection efficiency, Western blotting for 
PPARα was performed with both control and transfected cells.  
 
 
Results 
 
 
PPARα activity 
 
Treatment of HepG2 cells with ω3PUFA alone resulted in PPARα activity equal 
to that observed with recombinant PPARα, and DNA binding of PPARα was decreased 
by 70% in the presence of CDCA (p < 0.001). Treatment with CDCA and ω3PUFA 
resulted in less reduction of PPARα activity compared to controls. Although not 
significantly different from that of CDCA alone, there was a trend to restoration of 
PPARα activity with the addition of ω3PUFA (Figure 6-1).  
 
 
PPARα, LXR, and RXR expression 
 
Treatment with CDCA alone resulted in 67% reduction in PPARα expression as 
compared to cells treated with a vehicle control. Treatment with CDCA and the addition 
of ω3PUFA resulted in PPARα restored to the level of control (Figure 6-2). There was 
no statistical difference in expression of RXR (Figure 6-3). Treatment with CDCA alone 
resulted in a 2-fold increase in LXR expression that was attenuated by the addition of 
ω3PUFA (Figure 6-4). 
 
 
PPARα siRNA knockdown 
 
We were not successful in efficiently and consistently knocking down PPARα 
with siRNA. Studies were performed at time points from 24-96 hours; 48 hours had the 
most efficient knockdown, but this was not consistent and reliable enough to be able to 
perform experiments with confidence of achieving reliable results (Figure 6-5). 
 
 
Discussion 
 
Activity and expression of PPARα were reduced by treatment with lipophilic bile 
acid. When hepatocytes were exposed to ω3PUFA, PPARα expression and activity were 
increased. When cells were treated with CDCA with the addition of ω3PUFA, PPARα  
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Figure 6-1: PPARα activity. 
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Figure 6-2: PPARα mRNA expression. 
 
 
 
 
 
 
 
Figure 6-3: RXR mRNA expression. 
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Figure 6-4: LXR mRNA expression. 
 
 
 
 
 
 
 
Figure 6-5: PPARα siRNA knockdown. 
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expression and activity were similar to control cells. In studies of CFTR-knockout mice 
and isolated macrophages from CFTR-knockout mice pretreatement with DHA resulted 
in increased PPARα expression. This increase in PPARα expression was blocked by the 
addition of a PPARα antagonist (135, 136).  
 
We observed a 67% reduction in PPARα expression when cells were treated with 
CDCA as compared to cells treated with a vehicle control. The addition of ω3PUFA 
resulted in PPARα restored to the level of control. We did not observe a significant 
difference in expression of RXR, which was expected because of the abundance of RXR 
where it is not typically the rate limiting factor. However, treatment with CDCA alone 
resulted in a 2-fold increase in LXR expression that was attenuated by the addition of 
ω3PUFA. Typically, PPARα will form a heterodimer with RXR in order to be active and 
effect gene expression associated with inflammation and lipid regulation (137-140). 
Although RXR is usually associated with binding PPARα, recent studies have shown a 
high degree of cross-reactivity in binding among LXR, RXR, and FXR (141, 142). 
 
We completed several time studies with various concentrations of siRNA. We did 
successfully knock down PPARα, but these results were not consistent and we 
determined that proceeding forward with treatment studies exposing cells to CDCA and 
ω3PUFA might result in false results due to insufficient knockdown. Although we were 
not successful in achieving sufficient and consistent knockdown of PPARα, we plan to 
use a tetracycline inducible system in order to turn on/off PPARα. We believe this system 
will be more efficient and predictable.  
 
The decrease in PPARα with exposure to CDCA and subsequent increase of 
PPARα with ω3PUFA aligns with results in other studies of the anti-inflammatory and 
immunomodulatory effects of ω3PUFA (59, 65, 69, 130-132). These results suggest that 
PPARα activation may be a promising mechanism by which ω3PUFA attenuate the bile 
acid-induced hepatocellular injury that occurs in cholestasis, such as that seen in PNALD. 
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CHAPTER 7.    COLITIS ENHANCES LIVER INJURY AND INFLAMMATION 
IN A PRETERM PORCINE MODEL OF PARENTERAL NUTRITION-
ASSOCIATED LIVER DISEASE 
 
 
Background 
 
One of the most devastating diseases affecting premature neonates is necrotizing 
enterocolitis (NEC). NEC often requires surgical resection of the necrotic bowel, leaving 
the infant with short bowel syndrome (SBS). Infants and children with SBS have poor 
nutrient absorption and often require parenteral nutrition (PN). Although PN is lifesaving 
for many neonates and infants, it is not benign. Patients receiving long-term PN are at 
high risk for PN-associated liver disease (PNALD), which is one of the most devastating 
complications affecting infants receiving PN. The etiology of PNALD is not well-
understood and is likely multi-factorial (5-9). Risk factors include immature liver 
function, inflammation, oxidative stress, infection, nutrient deficiencies, and 
contaminants in parenteral products, as well the components of the PN, including lipid 
emulsions and amino acids (10-14). Lipid emulsions have been of particular interest in 
PNALD, as ω6PUFA soybean-based lipid emulsions are thought to be pro-inflammatory, 
as well as contain potentially toxic phytosterols (15). PNALD is reported to occur in 50–
66% of children receiving long-term PN, with a higher incidence in premature neonates 
(6-9, 16). If not reversed, PNALD can progress from cholestasis to liver fibrosis, hepatic 
failure, and death. Because of the complexity of this disease and need for prolonged 
hospitalization and home care, these patients are especially taxing to the healthcare 
system. Recent studies in human infants have shown improvement and even reversal of 
PNALD with intravenous omega-3 polyunsaturated fatty acid (ω3PUFA) 
supplementation (17-21). Although ω3PUFA supplementation has shown much promise 
in the treatment of PNALD, its mechanism of action is not well understood.  
 
Several animal models have been utilized to study PNALD and the effects of 
ω3PUFA supplementation on liver injury. A term neonatal pig model of PNALD has 
been used to study disease progression as well as treatment (143-145). In a mouse model 
of non-alcoholic fatty liver disease (NAFLD), hepatic fat content was highest in mice fed 
a liquid high-carbohydrate diet, and was significantly decreased by both enteral and 
parenteral ω3PUFA supplementation (59). In a surgical model of liver injury, mice 
underwent common bile duct ligation and were then randomized to receive a control diet 
rich in ω6PUFA or a diet rich in ω3PUFA. The diet rich in ω3PUFA resulted in a trend to 
be protective against injury, but this was not statistically significant (60). Interestingly, 
rabbits on PN that received fish oil were found to have more extensive hepatic fibrosis 
than those that received soybean or olive oil regimens (61), although the authors 
speculated that this adverse finding might be due to the ω-3 to ω-6 ratio of 1:6 in the 
emulsion studied, whereas optimal ω-3 to ω-6 ratios in animal models have ranged from 
1:2 to 1:4 (62, 63). Fish oil-based intravenous lipid emulsions have been shown effective 
in decreasing impairment of bile flow associated with PN administration in a term 
neonatal pig model, although the hepatic pathology was not characterized and the 
mechanism of action was not evaluated (145).  
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While a term neonatal pig model of PNALD has been used to study disease 
progression, as well as treatment (143-145), there are currently no published studies using 
a preterm pig model for the study of PNALD. A preterm pig model has been to study 
NEC (146-151), but has not been used for PNALD research. The objective of this study 
was to use a novel preterm neonatal pig model to evaluate enteral ω3PUFA as a treatment 
for PNALD and to evaluate liver injury after exposure to PN and colitis in a preterm 
porcine model. 
 
 
Materials and Methods 
 
 
Porcine model 
 
Preterm pigs were obtained via caesarian section at 92% gestation (day 106 of 
114-day gestation) from timed pregnant sows as described previously (147). After being 
stabilized, a central venous catheter (CVC) was inserted via the internal jugular vein, and 
PN solution administered as previously described (151). All animals received PN for the 
first 24 hours that provided (g/kg-d) glucose (22.3), amino acids (11.6) and lipids (6) 
Enteral nutrition was administered intermittently via an orogastric tube inserted at the 
time of CVC placement. Neonatal pigs were confined to metabolic incubators. All 
animals were euthanized and necropsied at the end of the study. 
 
 
Evaluation of ω3PUFA for the treatment of PNALD 
 
A brief pilot study with one litter of preterm (gestation 105/114 days) pigs was 
performed. Six pigs were sustained on PN and six pigs were enterally fed for one week. 
An additional six pigs were given PN with enteral ω3PUFA 1 g/kg/day (Lovaza®, Reliant 
Pharmaceuticals Inc., Liberty Corner, NJ) (152). This dose of ω3PUFA is based on 
preliminary data in human infants (153). 
 
 
Induction of colitis 
 
All animals received PN for the first 24 hours and were then randomized to 
enteral nutrition (EN), EN + colitis, PN, or PN + colitis. Colitis was induced with dextran 
sodium sulfate (DSS) given enterally every 12 hours for three doses starting 24 hours 
after delivery. Necropsy was performed on day 12.  
 
 
Sample collection 
 
Blood was collect at baseline and three days per week for the duration of the 
study. Direct bilirubin (DB), total bile acids (TBA), gamma-glutamyl transpeptidase 
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(GGT), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) 
concentrations were measured (performed by a contract reference laboratory). At the time 
of necropsy, serum, as well as snap-frozen and formalin-fixed liver, were collected for 
analysis.  
 
 
Histology 
 
At the time of necropsy, liver tissue was immediately placed in formalin. Slides 
were prepared with standard hematoxylin and eosin (H&E) staining. Liver histology was 
scored by a pathologist blinded to the experimental groups.  
 
 
Gene expression 
 
Liver RNA was extracted from frozen tissue to evaluate 84 key genes involved in 
inflammation using the Pig Inflammatory Cytokines and Receptors RT Profiler PCR 
Array system (SABiosciences, Frederick, MD) using quantitative RT-PCR.  
 
 
Results 
 
 
Evaluation of ω3PUFA for the treatment of PNALD 
 
In this one-week pilot study, there was a significant difference in direct bilirubin 
(DB) between pigs receiving PN and EN at days 3 and 7 (p = 0.000 and 0.0369, 
respectively; Figure 7-1). 
 
 
Induction of colitis 
 
Eighteen pigs were initiated. Nine pigs treated with DSS expired prior to the 
scheduled necropsy, and nine completed the 12-day protocol. Evaluation of weight, 
serum transaminases, direct bilirubin (DB), or total bile acids (TBA) was significantly 
higher in 12-day-old pigs compared to baseline. There was no difference in baseline 
AST, ALT, DB, or TBA among the four groups. At necropsy, mean DB and TBA were 
higher in the PN and PN+DSS groups compared to control, but this did not reach 
statistical significance (Figure 7-2).  
 
 
Histology 
 
Animals treated with PN developed mild steatosis, whereas animals treated with 
PN+DSS had moderate steatosis. In addition, PN+DSS pigs had significant ballooning  
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Figure 7-1: Direct bilirubin measurements in 7-day pilot study. 
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Figure 7-2: Liver functions at baseline and necropsy in 12 day-old pigs.  
AST, aspartate aminotransferase; ALT, alanine aminotransferase. 
 
 
 
 
 61 
 
degeneration and presence of Mallory bodies, but this was not observed in the other 
groups (Figure 7-3). 
 
 
Inflammatory gene expression 
 
Analysis of liver tissue from animals treated with PN+DSS compared to control 
(EN) identified 26 genes that were up- or down-regulated using a boundary of 4 when the 
two groups were plotted using 2-ΔCT (Figure 7-4). While these results are interesting, their 
validity is being confirmed using RT-PCR. 
 
 
Discussion 
 
The results from this study show that liver injury occurs in preterm pigs treated 
with PN. The results demonstrate: 1) treatment with enteral ω3PUFA results in 
significantly lower direct bilirubin in pigs treated with PN for seven days; 2) induction of 
colitis and PN results in significant liver injury observed by histology, but not clinically 
significant using biochemical markers after 12 days of PN; and 3) treatment with PN and 
induction of colitis results in up-regulation of pro-inflammatory gene expression in liver 
tissue from pigs treated for 12 days. 
 
After seven days of PN treatment we only observed a modest increase in direct 
bilirubin. Although these concentrations were within the normal limits for direct 
bilirubin, values were significantly higher in pigs that did not receive ω3PUFA 
supplementation in addition to PN. These modest increases in direct bilirubin are similar 
to the elevations in biochemical markers of liver disease reported by Kumar et al. in pigs 
treated with PN for 14 days (154). 
 
Because we only observed mild elevations in biochemical markers of liver injury 
in preterm pigs treated with PN for 7 day, for our next study we lengthened the treatment 
time to 12 days and induced colitis using DSS. El Kasmi et al. induced colitis in mice 
using DSS treatment combined with PN therapy (108). Animals treated with the 
combination of PN and DSS had lobular inflammation, hepatocyte apoptosis, peliosis, 
and Kupffer cell hypertrophy and hyperplasia. Colitis alone or PN alone did not result in 
liver injury or Kupffer cell activation (108). 
 
Based on these studies in mice, we induced colitis in a similar manner in the 
preterm pigs. Unfortunately, preterm pigs developed only mild hepatic biochemical 
changes after twelve days of PN. All biochemical markers were elevated in each of the 
four groups compared to baseline and animals treated with PN + DSS colitis had higher 
AST and direct bilirubin levels compared to control, but this was not statistically 
significant because of the high variability among animals. Bile acids were increased in 
animals treated with PN, but again this finding was not significant. Given the lack of 
statistical differences in biochemical markers of liver injury it would be very difficult to 
use this model for studies involving interventions to treat PNALD. 
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Figure 7-3: Liver histology in 12 day-old pigs.  
DSS, dextran sodium sulfate; EN, enteral nutrition; PN, parenteral nutrition. 
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Figure 7-4: Inflammatory gene changes in preterm pigs.  
Red stars above the lines signify genes that were up-regulated and green stars below the 
line signify genes that were down-regulated. 
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Despite the lack of biochemical evidence of liver injury, histological changes 
were present. The degree of steatosis increased when a colitis insult was combined with 
PN treatment. The histological evidence is encouraging that we were successful in 
inducing PNALD in the preterm pig using both PN and colitis, but without clear 
biochemical evidence the utility of this model is limited. 
 
Other porcine models of PNALD using term pigs have not induced colitis (155), 
yet they have been successful in seeing only modest biochemical changes and 
histological evidence of liver disease. This has allowed expansion of the treatment time to 
several weeks. This group is using term pigs rather than preterm pigs, which, because of 
the increased size and stability securing intravenous access and maintaining overall 
stability, may be slightly easier, yet with term pigs one loses the risk factor of 
prematurity.  
 
Liver mRNA analysis revealed up and down-regulation of 26 key inflammatory 
genes in pigs treated with PN+DSS compared to EN. While these findings are interesting, 
further evaluation of these genes is needed in order to elucidate specific inflammatory 
pathways affected by ω3PUFA in this model of PNALD. This supports others findings 
that an initial intestinal insult that increases gut permeability leads to translocation of 
toxins and inflammatory mediators from the gut into the hepatic circulation, which leads 
to activation of Kupffer cells (108).  
 
These studies have shown that only modest biochemical changes in liver 
functions occur in preterm pigs treated with PN and DSS for a 12-day period. 
Histological changes including increased hepatic fat accumulation are present in pigs 
treated with PN and DSS. The addition of DSS-induced colitis increases the severity of 
PNALD and liver inflammation. These data suggest that gut inflammation has a 
significant impact on liver health in the preterm pig exposed to PN. 
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CHAPTER 8.    DISCUSSION AND CONCLUSION 
 
 
Summary of Results 
 
My entire research program thus far was inspired by a clinical observation. This 
dissertation tells the story of my research pursuits over the past five years. I first focused 
on bile acid-induced apoptosis. I have shown that the lipophilic bile acid CDCA can 
induce hepatocellular apoptosis and that this is attenuated by ω3PUFA. Interestingly, we 
found that the combination of EPA and DHA was synergistic in the attenuation of 
CDCA-induced apoptosis measured by evaluation of caspase-3/7. I was the first to show 
the synergy between EPA and DHA and I have experiments currently underway to 
evaluate specific ratios of EPA to DHA in hopes of determining the most optimal ratio. 
 
I also showed that apoptosis primarily occurs via death receptors on the cell 
surface; in particular, the Fas receptor is associated with bile acid-induced apoptosis, and 
when Fas is blocked with an antibody, apoptosis is attenuated. Collaboration with 
colleagues using a mouse model of PNALD allowed us to evaluate Fas, Fas-L, TRAIL-
R2, and TRAIL expression in vivo. We observed an increase in Fas expression in mice 
treated with PN compared to mice fed standard chow, and a decrease in TRAIL in mice 
treated with PN compared to mice fed standard chow. These trends, whether up (as in the 
receptor Fas) or down (as in the ligand TRAIL), were more exaggerated with duration of 
time spent on PN. This in vivo observation in the mouse model of PNALD strengthened 
our in vitro findings that bile acid-induced apoptosis occurs via death receptor-dependent 
mechanisms. While apoptosis has been studied in models of injury (156), it has not been 
extensively evaluated with respect to the attenuation of PNALD by ω3PUFA. We are the 
first to show alteration in death receptors and ligands in an in vivo model of PNALD. 
 
Apoptosis and inflammation associated with PNALD is not limited to hepatocyte 
injury and may also involve the activation of Kupffer cells in the liver. I have shown that 
ω3PUFA attenuate bile acid-induced apoptosis in a macrophage model, ω3PUFA 
attenuated inflammation via IL-1β and TNF-α in a macrophage model, and macrophage 
stimulation with lipophilic bile acid and endotoxin increased NFκ-B expression in 
hepatocytes. While these experiments are very elementary, they provide the basis for 
more exploration in the role of macrophage activation in PNALD. Whether activation of 
Kupffer cells occurs via LPS migration from the gut (118), or via toxic components from 
the PN solution such as phytosterols (19, 73), most investigators studying liver injury 
agree that Kupffer cell activation is key in the development of fibrosis and end stage liver 
disease (156). 
 
In addition to exploring mechanisms of bile acid-induced apoptosis we also 
evaluated mechanisms by which ω3PUFA attenuate hepatocellular injury. For these 
experiments we evaluated the effects of both EPA and DHA. We showed that EPA and 
DHA were synergistic in attenuating apoptosis when evaluating caspase-3/7 activity, but 
no synergy was observed with Fas and TRAIL-R2 expression. These findings led me to 
explore other possible mechanisms by which ω3PUFA could be attenuating 
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hepatocellular injury. Omega-3 PUFA are known ligands of PPARα, therefore we 
evaluated both PPARα activity and expression in hepatocytes treated with CDCA with 
and without EPA and DHA. Treatment with CDCA resulted in a decrease in both PPARα 
activity and expression, and this was restored to the level of control when hepatocytes 
were treated with ω3PUFA. We also evaluated the nuclear receptors RXR and LXR, 
which are essential for the formation of active PPARα heterodimer. RXR expression was 
unchanged with treatment with CDCA and ω3PUFA, but LXR expression was increased 
2-fold with treatment with CDCA and attenuated to the level of control with the addition 
of ω3PUFA. We attempted to use RNA interference to decrease expression of PPARα so 
that we could further elucidate mechanisms by which ω3PUFA were altering this PPARα 
and expression. We were unsuccessful at achieving a consistent and efficient knock-
down. We tried transfecting cells with several different primer designs for PPARα and 
tried a double transfection with two different sets of primers, but did not achieve 
sufficiently consistent knock-down. Rather than spend more time and resources to try to 
make this technique work, we will try a tetracycline inducible system to turn off PPARα. 
The role of PPARα is important in both inflammation and apoptosis. The other nuclear 
receptors, RXR, LXR, FXR and PXR, have all been identified as important factors in 
cholestasis and bile acid transport (135, 136, 157).  
 
Besides using an isolated cell culture model of hepatocytes and macrophages 
involved in PNALD, we also used a preterm neonatal pig model of PNALD. The results 
from this study show that liver injury occurs in preterm pigs treated with PN. We showed 
that treatment with enteral ω3PUFA results in significantly lower direct bilirubin levels in 
pigs treated with PN for seven days, yet this difference was modest. In hopes of 
increasing the severity of PNALD, we lengthened the treatment time and induced colitis. 
Induction of colitis and PN resulted in significant liver injury as observed by histology, 
but it was not clinically significant, as judged by biochemical markers after 12 days of 
PN. Treatment with PN and induction of colitis results in up-regulation of pro-
inflammatory gene expression in liver tissue from pigs treated for 12 days. Although we 
were not impressed with the degree of change in biochemical markers of liver injury in 
pigs treated with PN, our findings were similar to serum markers in term pigs treated with 
PN (155). The results of the inflammatory array will be a valuable tool to use to confirm 
important inflammatory genes involved in colitis that may be early indicators of PNALD. 
 
 
Future Directions 
 
Thus far I have shown that ω3PUFA attenuate apoptosis in hepatocytes and have 
proposed several mechanisms by which this may be occurring. As mentioned in the 
introduction, PNALD is a multi-factorial disease and a clear etiology is unknown. 
However, we do know that PN is associated with a loss of intestinal epithelial barrier 
function, which can lead to intestinal dysfunction and the transit of luminal toxins (such 
as LPS and TNF) into the host. This increased intestinal permeability is thought to play a 
role in the development of PNALD (113). We also know that PN alone may not result in 
PNALD, as animal models require induction of an experimental colitis in addition to PN 
in order to observe substantial liver injury. Although the liver is the site of disease and we 
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have shown that ω3PUFA attenuate bile acid-induced apoptosis in hepatocytes, the liver 
may not be the root of the problem.  
 
I hypothesize that ω3PUFA are attenuating inflammation and apoptosis in the gut, 
leading to a decrease in intestinal permeability and less migration of inflammatory 
mediators from the gut to the liver. Our initial observations in human infants treated with 
enteral fish oil resulted in improvement in liver injury within two weeks of initiation of 
therapy. This was much sooner than what was observed in human infants treated with IV 
fish oil where the mean time to resolution of PNALD was four weeks. We hypothesized 
that ω3PUFA administered enterally may have an added benefit over the IV preparation 
as it may have a localized anti-inflammatory effect on the gut. While this hypothesis has 
not been proven in this dissertation, my next step in my pursuit of understanding how 
ω3PUFA attenuate PNALD will be to focus on the effects of ω3PUFA on the gut and the 
impact on liver injury. 
 
My next aim will be to identify attenuation of intestinal injury and PNALD in 
vivo by ω3PUFA. For this aim I will use a mouse model of PNALD. In contrast to the pig 
model, the mouse model has been shown by other investigators to produce reliable 
biochemical markers of liver injury so that many treatments may be evaluated prior to 
necropsy. Corollaries of my central hypothesis are that [i] both enteral and parenteral 
administration of ω3PUFA will be associated with attenuation of intestinal insult and 
PNALD when compared to animals receiving PN without ω3PUFA, and [ii] animals 
receiving enteral ω3PUFA will have enhanced attenuation of both intestinal and liver 
injury compared to animals receiving parenteral ω3PUFA. While I will be interested in 
the overall progression or presence of PNALD in animals, I would like to specifically 
evaluate intestinal permeability in regards to ω3PUFA. To test this, I will evaluate both 
protein and RNA expression of the tight junction proteins occludin and claudin-1, which 
are essential in maintaining barrier function in the gut. I will also orally administer a 
radio-labeled protein to determine changes in barrier function related to PN. At the time 
of necropsy, radioactivity will be measure in serum, gut tissue, and liver tissue and 
compared to control animals. I will also examine intestinal apoptosis. At first thought one 
would expect that significant apoptosis would automatically result in loss of barrier 
function and disruption of tight junctions, but because of the crypt-villus organization of 
the gut, substantial apoptosis can occur in the crypt without significant disruption of tight 
junctions. 
 
In my second aim, I will evaluate ω3PUFA effect in endotoxin stimulated 
intestinal epithelial cells. I anticipate that ω3PUFA will attenuate intestinal injury via 
GPR120 dependent pathways. Omega-3 PUFA are a ligands for G protein-coupled 
receptor 120 (GPR120). The therapeutic mechanism of ω3PUFA attenuation of in 
PNALD is unknown, but is thought to occur via anti-inflammatory pathways, as of yet 
undefined. Although GPR120 has been shown to be an important pathway for ω3PUFA 
positive impact on obesity and diabetes, its role in PNALD has not been explored. 
 
For these experiments I will use Caco2 cells and treat with LPS with and without 
the addition of ω3PUFA. I will first evaluate changes in barrier function using 
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unidirectional flux of inulin. I will also use immunoflurescence microscopy tight junction 
and apoptotic proteins. I will then specifically look at the role of GPR120 in regards to 
the protective effect of ω3PUFA on preserving intestinal barrier function. I will first 
measure RNA expression of GPR120 and then I will use siRNA techniques to 
knockdown GPR120 and evaluate tight junctions as described above. Once this 
hypothesis has been validated, I would like to further confirm this as a mechanism of 
ω3PUFA attenuating PNALD by using GPR120 knockout mice (96) and treat with PN 
with and without ω3PUFA. 
 
With respect to expected outcomes, the work proposed in Aim 1 will determine if 
there is a local intraluminal effect of enterally administered ω3PUFA in an animal model 
of PNALD. The work proposed in Aim 2 will focus on mechanisms in which ω3PUFA 
modify inflammation, apoptosis, and ultimately intestinal epithelial barrier function. The 
results are expected to have an important positive impact by filling a key gap in the 
understanding of the mechanism of ω3PUFA in the attenuation of intestinal insult. My 
research will provide explanation into the interplay between intestinal and liver disease, 
which is imperative to the development of novel therapeutic interventions. 
 
 
Conclusions 
 
The results presented here have made some progress in determining how 
ω3PUFA attenuate PNALD, but there are still potentially a lifetime of questions that are 
still left unanswered. I believe the skills that I have learned from course work and 
research experience as a part of the requirements for my Doctor of Philosophy degree 
have prepared me to refine a research question, make a valid hypothesis, and design 
experiments to test the hypothesis. I hope that my future aims will have an important 
positive impact by filling a key gap in the understanding of the mechanism of ω3PUFA 
in the attenuation of both intestinal and liver insult.  
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